Neuer Start, neuer Risk!!! - 500 Beiträge pro Seite

[Shanghai2006]

Auf ein Neues!

[Shanghai2006]

Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that the European Commission has granted orphan drug status to a broad range of Cytori Cell Therapy® formulations when used for the treatment of hand dysfunction and Raynaud’s Phenomenon in patients with scleroderma.

Key benefits of this broad orphan drug designation include: (1) the ability to pursue multiple therapeutic formulations for systemic scleroderma that are not restricted to the processing of the adipose-derived cellular therapeutics at the bedside with the Celution® System or other current technology, (2) allows adipose-derived cellular therapeutics that are cryopreserved for later administration and (3) provides a pathway for Cytori to expeditiously seek conditional market approval in the EU.

“This broad orphan designation expands our strategic regulatory position and commercial options in Europe,” said Marc Hedrick, President and CEO of Cytori Therapeutics. “We intend to rely on this orphan designation, as well as long term safety and efficacy data from the SCLERADEC-I trial to seek conditional market authorization from the European Medicines Agency (EMA) on an accelerated timeline.”

“Orphan designation in Europe comes with significant benefits,” said Kenneth K. Kleinhenz, Vice President of Global Regulatory Affairs and Quality Assurance of Cytori Therapeutics. “These benefits include up to 10 years of market exclusivity if the medicine is authorized by the European Medicines Agency (EMA), access to the EMA’s conditional marketing authorization pathway (which is designed for orphan products that have initial clinical data and are actively in the process of completing their pivotal clinical studies), and an additional 10% reduction in regulatory fees beyond the reductions already afforded us because of our SME status. We believe the ECCS-50 therapy for scleroderma may benefit from these accelerated programs in Europe. This broad orphan designation will play a key role in our ability to fully access these programs.”

More information about the orphan drug designation process and the potential advantages of orphan designation within the European Union can be found at the EMA website.


Link: http://www.streetinsider.com/Corporate+News//Cytori+Therapeu…

[scor1337]

nach allem was ich bis jetzt mitbekommen habe, geht es doch nur darum, dass hier geld verbrannt wird...
nmM

[wilmore]

Antwort auf Beitrag Nr.: 52.418.235 von scor1337 am 16.05.16 22:21:05

Zitat von scor1337: nach allem was ich bis jetzt mitbekommen habe, geht es doch nur darum, dass hier geld verbrannt wird...
nmM

na ja ... Börse ist halt das Handeln der Zukunft. Gerd verbrennende Unternehmen gibt es genug und das schliesst astronomische Kurse & Bewertungen nicht aus. Schon mal bei Tesla vorbei geschaut? By the way - z.B. im IT Bereich haben es bisher nur wenige von der Vision wirklich in ein Geschäftsmodell umsetzen können - Google und Apple würde ich zu zählen und überraschender Weise auch Facebook was ich nie geglaubt hätte.

Mit Biotech ist das halt so ne Sache .... allein das Sclodermia treatment wenn eine Zulassung bekommt kann schon ordentlich Cash abwerfen. So Hoffnungslos ist das Ganze also nicht..... warten wir's ab. Auf jeden Fall brauchst du bei Cytori einen Langen Atem und Geduld.....

[scor1337]

Antwort auf Beitrag Nr.: 52.424.457 von wilmore am 17.05.16 19:00:46

Ja nur dass hier in die eigene Tasche gewirtschaftet wurde, siehe alter Thread.

[Blackwater01]

Antwort auf Beitrag Nr.: 52.418.235 von scor1337 am 16.05.16 22:21:05

Bios bergen immer eine große Gefahr....durch KE..Splits..ect.
Bis zur Marktreife eines Medis...bezahlen die Anleger in der Regel alles..von einigen Milestonezahlungen bei Bios mal abgesehen....

Zum Traden ist CYTX derzeit sehr gut geeignet....klasse Vola..Volumen..ect.

Bei dem sich gebildeten Momentum seid gestern....vermute ich einen Lauf bis in den Bereich der 5-6$ Marke in den kommenden Handelstagen.

Ich bin auf jeden Fall hier mit dabei...

Good Luck den Investierten hier !

[Zimtzicke]

Antwort auf Beitrag Nr.: 52.427.619 von Blackwater01 am 18.05.16 08:48:35

..das wäre mal was....5-6

[scor1337]

Dazu würde ich auch nicht nein sagen, noch bin ich investiert, da ich nicht aussteigen könnte

[Shanghai2006]

News:CYTX discloses plans to present an update on use of its Cytori CEll Therapy in the French SCLERADEC I and II clinical trials

Read more: http://www.nasdaq.com/article/health-care-sector-update-for-…

[nicotoll9]

Hallo Leute Kursziel 22 - 75 Dollar wäre nicht schlecht



Anteile von Cytori Therapeutics Inc (NASDAQ: CYTX) mit einem durchschnittlichen Broker Ratingnote von 1,00 (Strong Buy) von den beiden Analysten, die die Aktie, Zacks Investment Research-Berichte decken zugewiesen wurden. Zwei Aktien-Analysten haben die Aktie mit einem starken Kaufempfehlung bewertet.

Brokerages haben ein Jahr Konsens Zielpreis von $ 119,94 für das Unternehmen eingestellt und erwarten, dass das Unternehmen ($ 0,60) EPS für das laufende Quartal wird Post nach Zacks. Zacks hat auch Cytori Therapeutics eine Branche Rang 162 von 265 basierend auf den Bewertungen gegeben zu seinen Wettbewerbern zugeordnet.

In anderen Nachrichten erworben Director David Rickey 150.000 Aktien der Aktien der Firma in einer Transaktion am MITTWOCH, 9. März. Die Aktien wurden zu einem durchschnittlichen Preis von $ 0,19 je Aktie gekauft, mit einem Gesamtwert von $ 28.500,00. Die Akquisition wurde in einer Einreichung bei der SEC offenbart, die durch diesen Hyperlink verfügbar ist.






Cytori Therapeutics (NASDAQ: CYTX) eröffnet am 2.97 am Dienstag. Die Marktkapitalisierung des Unternehmens ist 39,60 Millionen US $. Die 50 Tage Aktie gleitenden Durchschnittspreis ist 3,83 $ und der 200 Tage gleitenden Durchschnittspreis beträgt $ 3,56. Cytori Therapeutics hat eine 52-Wochen-Tief von $ 1,95 und ein 52-Wochen-Hoch von $ 11.25.

Cytori Therapeutics (NASDAQ: CYTX) hat zuletzt das Quartalsergebnis Ergebnisse am Dienstag 10. Mai. Das Unternehmen berichtet ($ 0,41) Ergebnis je Aktie (EPS) für das Quartal, die Konsensschätzung von ($ 0,03) von 0,38 $ fehlt. Das Unternehmen verdiente $ 2,90 Mio. im Quartal im Vergleich zu den Erwartungen der Analysten von $ 2.050.000. Das Unternehmen Quartalsumsatz stieg um 26,1% im Vergleich zum gleichen Quartal des Vorjahres. Im gleichen Zeitraum des Vorjahres erzielte das Unternehmen ($ 0,07) EPS. Analysten gehen davon aus, dass Cytori Therapeutics (26,63 $) das Ergebnis je Aktie für das laufende Jahr veröffentlichen wird.

Mehrere Broker hat kürzlich Berichte über CYTX. Zacks Investment Research aktualisiert Cytori Therapeutics aus einem Rating "halten" auf ein Rating "buy" und legen Sie einen $ 3,75 Kursziel für das Unternehmen in einem Bericht über Montag, 1. Februar. Roth Kapital wiederholte ein Rating "buy" und gab eine 22,50 $ Kursziel für Aktien von Cytori Therapeutics in einem Bericht über Montag 8. Februar. Schließlich bekräftigte Maxim Group Rating "buy" und gab eine $ 75,00 Kursziel für Aktien von Cytori Therapeutics in einem Bericht über Montag, 8. Februar.

Cytori Therapeutics, Inc. (Cytori) ist ein Biotechnologie-Unternehmen in der Entwicklung von Behandlungen beteiligt und Geräte für eine Reihe von Erkrankungen Zellen als wichtiger Bestandteil der Therapie. Die Gesellschaft ist für Patienten mit Sklerodermie Hand Dysfunktion, orthopädischen Erkrankungen, Herz-Kreislauf- Erkrankungen, Harninkontinenz und thermische Verbrennungen bei der Entwicklung von Primärprodukt, Cytori Zelltherapie, engagiert mit Strahlenschäden kombiniert.

[zocker1564]

Cytori Announces Commencement of Subscription Period for Previously Announced Rights Offering
Nachrichtenquelle: Business Wire (engl.) | 31.05.2016, 13:00

Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today it has commenced the subscription period for its previously announced rights offering of up to 6,896,551 units consisting of shares of common stock and warrants to purchase shares of common stock to existing stockholders. The rights offering will remain open until 5:00 PM Eastern Time on Thursday, June 9, 2016, unless extended. Rights holders will need to exercise their subscription rights prior to that date and time.

If exercising subscription rights through a broker, dealer, bank or other nominee, rights holders should promptly contact their nominee and submit subscription documents and payment for the units subscribed for in accordance with the instructions and within the time period provided by such nominee. The broker, dealer, bank or other nominee may establish a deadline before June 9 by which instructions to exercise subscription rights, along with the required subscription payment, must be received.

All record holders of rights certificates that wish to participate in the rights offering must deliver a properly completed and signed rights certificate, together with payment of the subscription price for both basic subscription rights and any oversubscription privilege election, to the Subscription Agent, to be received before 5:00 PM Eastern Time on June 9, 2016. The Subscription Agent is:

By mail: By hand or overnight courier:
Broadridge Corporate Issuer Solutions, Inc.
Attn: BCIS Re-Organization Dept.
P.O. Box 1317
Brentwood, New York 11717-0693
[phone] (toll free)

Broadridge Corporate Issuer Solutions, Inc.
Attn: BCIS IWS
51 Mercedes Way
Edgewood, New York 11717
[phone]

Under the rights offering, Cytori has distributed one non-transferable subscription right for each share of common stock held on the previously announced record date of May 20, 2016. Each right entitles the holder to purchase one unit at the subscription price of $2.90 per unit, composed of one share of common stock and 0.5 of a warrant, with each whole warrant exercisable to purchase one share of common stock at an exercise price of $3.48 per share for 30 months from the date of issuance. Cytori has applied to list the warrants on NASDAQ, although there is no assurance that a sufficient number of subscription rights will be exercised so that the warrants will meet the minimum listing criteria to be accepted for listing on NASDAQ under the symbol “CTYXW.” The warrants may be redeemed by Cytori prior to their expiration if Cytori’s common stock closes above $8.70 per share for 10 consecutive trading days. The subscription rights are non-transferrable and may only be exercised during the anticipated subscription period commencing today through 5:00 PM ET on Thursday, June 9, 2016, unless extended. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission.

Holders who fully exercise their basic subscription rights will be entitled, if available, to subscribe for an additional amount of units that are not purchased by other stockholders, on a pro rata basis and subject to ownership limitations.

Cytori has engaged Maxim Group LLC as dealer-manager for the rights offering.

Each stockholder of record as of May 20, 2016 will receive by mail an information packet that explains the rights offering. Stockholders with specific questions are urged to contact Broadridge Corporate Issuer Solutions, Cytori's information agent for the rights offering, by calling [phone] (toll-free); or Maxim Group LLC, 405 Lexington Avenue, New York, NY 10174, Attention Syndicate Department, email: [e-mail] or telephone [phone].

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The Company's registration statement on Form S-1 was declared effective by the U.S. Securities and Exchange Commission (SEC) on May 26, 2016. The prospectus as well as prospectus supplement no. 1 thereto dated May 31, 2016 and all of the Company's SEC filings may be found in the Investor Relations section of Cytori's website at www.ir.cytori.com.

[nicotoll9]

6 juni
8 juni
23 juni
29 juni
ist Cytori auf Konferenzen :-)
ich glaube wir stehen nahe an einem gewaltigen Kurssprung.........

[Zimtzicke]

http://www.wallstreet-online.de/nachricht/8668313-presentati…

[nicotoll9]

Natürlich gehören die alle in den Knast......bin aber leider noch drinnen, meine verluste sind gewaltig...

6 juni
8 juni
23 juni
29 juni
ist Cytori auf Konferenzen :-) Nur supertolle news, wenn jetzt Panterschaften gelingen Phase Skl. 3
unsw. dan kann es doch noch passieren.....
ich glaube wir stehen nahe an einem gewaltigen Kurssprung.........

[nicotoll9]

Dr. Cugat könnte sehr gut Daten an den Tisch bringen, die einen wesentlichen Einfluss auf die Marktwahrnehmung der Wirksamkeit von ADRC haben. Gemäß der Mitteilung:

"Daten vorgelegt werden gehören Sicherheit, Machbarkeit, Patienten berichteten Ergebnisse in Bezug auf Aktivität und Schmerzen sowie serielle Magnetresonanztomographie (MRT) des Knies durch ein Jahr."

MRI-Daten über den Verlauf eines Jahres Behandlungsstandard verglichen ist sehr bedeutsam. Wenn es eine visuelle Korrelation / Reaktion zeigt, die mit einer positiven Reaktion in den anderen Ergebnissen vis a vis SOC angemessen ist, würde man sich fragen, ob es nicht eine ähnliche Reaktion in der OA-Studie sein kann von Cytori durchgeführt werden?

Dov, die "bemerkenswert" Erectile Dysfunction Indikation ist sehr interessant und hat völlig unbemerkt geblieben. Was auch von großem Interesse ist, ist die Aussage von Dr. Haahr: "Wir planen bereits eine doppelblinde, randomisierte Follow-up-Studie."

ADRC werden in einer großen Anzahl von Indikationen von denen viele getestet Leben für Patienten und uns als Investoren zu ändern sein könnte. Ich hoffe, dass nach der Ausgabe Rechte der Forscher Studien führte eine größere Sichtbarkeit von der Firma erhalten wird ..

Wenn die ersten Daten aus dem Französisch Ermittler Studie für eine kleine Anzahl von Sklerodermie-Patienten führte veröffentlicht wurde ich sah sofort, dass es niedrig hängenden Früchte, war und sagte, so viel auf diesem Message Board vociferously. Die andere Angabe, die mich verhext ist die cryptoglandula Fistel und Fistel im allgemeinen Indikationen. Ein großer medizinischer Bedarf an dem wir eine Behandlung haben. Warum die Verzögerung ?????

In aller Ehrlichkeit sollten wir nicht in dieser Situation sein. Diese Plattform kann die Behandlung einer Vielzahl von Indikationen revolutionieren.

Viele schlagen vor, dass wir aufgrund der dem 48-Wochen-Analyse der Sklerodermie (STAR) Versuchsdaten und die anschließende Einreichung an die FDA mit der angemessenen Wartezeit auf die Märkte für Kapital gehen müssen wird zurück. Ich möchte darauf hinweisen, dass die primäre Indikation die 24 Wochen Cochin ist Punktzahl mit den wichtigsten sekundären Indikationen hätten 1. Raynaud-Condition Score und 2. Sklerodermie Health Assessment Questionnaire (SHAQ), beide sind 24 Wochen Datensätze. Diese Daten werden viel früher als 48 Wochen. Wenn es wie die früheren Studien die Erfolgswahrscheinlichkeit Spuren steigt geometrisch ......... und tun so die Freier.

[zocker1564]

Cytori Cell Therapy™ Leads to Improved Function and Reduced Scar Tissue in a Urinary Injury Model
Business Wire Cytori Therapeutics, Inc.
3 minutes ago

SAN DIEGO--(BUSINESS WIRE)--

Cytori Therapeutics, Inc. (CYTX) announced today the publication in The Journal of Urology of a preclinical study applying Adipose-Derived Regenerative Cells (ADRCs) prepared using Cytori Cell Therapy in a large animal model of urethral injury.

The results show that delivery of the cell therapy product immediately after injury resulted in a >50% decrease in fibrotic scar tissue from 17% of total urethral surface area in the control to 7% in the treated group (p=0.05) 30 days following treatment. The study further reported that delaying delivery of the cell therapy product until 30 days after injury—a time at which urethral fibrosis was well-established—led to >10-fold decrease in injured surface area (from 13% of the urethra in the control group to 1% in the treated group; p<0.05) at 60 days after injury (30 days after treatment). ADRC-treatment was also associated with a statistically significant increase in the maximum pressure generated by the urethra, an important component of urinary sphincter function.

This study was led by Drs. Giles Karsenty and Romain Boissier of Aix-Marseille University in Marseille, France supported by the team of Pr. Florence Sabatier of the Cell Therapy Department of Hôpital de le Conception, Assistance Publique-Hôpitaux de Marseille.

“These now published findings support the use of either immediate or delayed application of Cytori Cell Therapy to help reduce injury and scarring,” said Dr. Marc Hedrick, President and CEO of Cytori. “This important safety and proof of concept preclinical study will be useful in forthcoming regulatory submissions in the US, Europe and Japan.”

Data from this preclinical study supported the company’s recently enrolled the STAR clinical trial, an FDA-approved, 88 patient, multi-center, randomized controlled Phase III trial of Cytori Cell Therapy for the treatment of hand dysfunction and Raynaud’s Phenomenon in patients with scleroderma as well as the investigator-initiated, ADRESU urinary incontinence trial currently enrolling in Japan. A reduction in cutaneous fibrosis as measured by the modified Rodnan Skin Score (mRSS) of the hand was also noted in the previous published SCLERADEC I clinical trial.

[nicotoll9]

SAN DIEGO & TOKIO - (BUSINESS WIRE) - Cytori Therapeutics, Inc. (NASDAQ: CYTX) gab heute bekannt, dass die Verwendung von Cytori Cell Therapy ™ wurde für die klinische Anwendung am 24. Juni genehmigt, 2016 Knie-Arthrose auf der Tokyo Osteoarthritis zu behandeln Klinik unter dem "Gesetz über die Sicherheit der Regenerative Medizin 'Japanisch, die am 25. November 2014 in Kraft gesetzt wurde.

Tokyo Osteoarthritis Klinik wird sofort beginnen Knie-Arthrose-Patienten mit Cytori Zelltherapie zu behandeln. Diese Genehmigung unterliegt den Einrichtungen im Rahmen der Klinik Schirm beschränkt, sondern schränkt die Zahl der Patienten, die behandelt werden können. Solche Zulassungen werden von dem sozialen Gesundheitssystems nicht erstattet und die Patienten werden die Kosten für die Behandlung verantwortlich.

"Osteoarthritis ist sehr verbreitet in Japan und die neue Gesetzgebung gibt uns einen zugelassenen Weg neuartige regenerative Therapien für die Patienten heute zu machen", sagte Dr. Masayuki Yamakawa, CEO der Tokyo Osteoarthritis Clinic.

In Japan wurde eine Klasse-I-Meldung Celution-System von Cytori gewährt ursprünglich im Jahr 2012. Die jüngste Gesetzgebung im Jahr 2013 von der japanischen Diät ursprünglich weitergegeben und später erlassen und durchgesetzt werden, stellt einen Mechanismus führenden Gesundheitseinrichtungen in Japan ermöglichen, bestimmte Technologien der regenerativen Medizin zu verwenden, gilt als innovativ und sicher von der japanischen Regierung für bestimmte Indikationen, wenn sie von einem zertifizierten und akkreditierten regenerativen Medizin Ausschuss genehmigt.

"Die innovative regenerative Medizin Gesetz vor kurzem in Japan zugelassen Möglichkeiten für therapeutische Innovation für Cytori erweitert schafft", sagte John Harris, Cytoris Vice President & General Manager, Zelltherapie. "Diese Registrierung und die in der Zukunft zu erwarten sollten wichtige Elemente sein, uns zu helfen Zugang für unsere Cytori Zelltherapie zu einer großen Population von Patienten in Japan mit Arthrose leiden erweitern. Für die Tokyo Osteoarthritis Clinic, ist dies ein wichtiger Meilenstein, und ich glaube, dass sie für die Führung in Arthritis-Therapie in Japan gut aufgestellt sind. "

Über Cytori

Cytori Therapeutics ist ein spätes Stadium der Zelltherapie Unternehmen in der Entwicklung autologer Zelltherapien aus dem Fettgewebe eine Vielzahl von Erkrankungen zu behandeln. Daten aus präklinischen Studien und klinischen Studien deuten darauf hin, dass Cytori Cell Therapy ™ wirkt in erster Linie durch den Blutfluss zu verbessern, das Immunsystem modulieren und Wundheilung zu erleichtern. Als Ergebnis Cytori Cell Therapy ™ kann Vorteile über mehrere Krankheitszustände liefern und kann am Point-of-Care durch Cytori eigenen Technologien und Produkte für den Arzt und Patienten zur Verfügung gestellt werden. Für weitere Informationen besuchen www.cytori.com.

Über Tokyo OA Clinic

Tokyo OA Clinic ist eine engagierte Knie-Arthrose Klinik unter "Die Klinik-Gruppe." Die angeschlossenen Ärzte verwenden Durchbruch Technologie Osteoarthritis zu behandeln. Ihr Team arbeitet eng mit der Wissenschaft, Klinik und Industrie hohe Behandlungen für Patienten in Japan zu bringen. Für weitere Informationen, besuchen Sie bitte https://www.knee-joint.net/. Für Medienanfragen wenden Sie sich bitte an Frau Yanagino, 03-6455-5307; Patienten können 0120-013-706 nennen.

[Shanghai2006]

Thirty-one patients (17 Cytori Cell Therapy, 14 placebo) were randomized prior to termination of enrollment, with 28 patients having 6 month or longer follow-up data. Trial enrollment was terminated prior to the planned target (45 patients per trial) due to the prolonged period of enrollment and safety reviews. ATHENA and ATHENA II trial data were combined for analyses. The key results were as follows: Improvements in the Minnesota Living with Heart Failure Questionnaire (MLHFQ) total score (a validated questionnaire for disease specific health related quality of life) were observed in the Cytori Cell Therapy group relative to the placebo group. The mean (95% CI) between group differences (Cytori Cell Therapy minus placebo) for the change from baseline were as follows: 3 months = -4.7 (-20.3, 10.9) (p=0.54) 6 months = -9.4 (-22.5, 3.8) (p=0.154) 12 months = -16.3 (-31.7, -1.0) (p=0.038). The SF-36 (a validated questionnaire for generic health related quality of life) results showed trends toward improvement in the Cytori Cell Therapy group relative to the placebo group, with several domains associated with nominal p-values less than 0.05. At 12 months, New York Heart Association class improved in 57% of ADRC-treated patients compared to 15% of placebo patients. The corresponding values for the Canadian Cardiovascular Society class were 67% and 27%. Echocardiogram and treadmill testing was performed at baseline and 6 months post-treatment. The mean change from baseline to 6 months in maximum oxygen consumption was 45.4±222 mL/min (ADRC, n=15) vs. -9.5±137 mL/min (placebo, n =10) [mean (95% CI) between group difference = 54.9 (-109, 219), p=0.495]. Left ventricular ejection fraction, left ventricular end-systolic volume and left ventricular end-systolic volume showed no relevant differences between groups. Heart failure hospitalizations were reported in 3/17 (17.6%) and 5/14 (35.7%) of cell treated and placebo treated groups respectively. Central adjudication of these events showed the respective numbers to be 2/17 (11.7%) and 3/14 (21.4%). Regarding safety, 18 of 31 patients (58.1%) were reported to have at least one serious adverse event during the trial (Cytori Cell Therapy 9/17 (52.9%), placebo 9/14 (64.3%)). Major Adverse Cardiovascular Events (MACE) occurred in 6/17 (35.3%) of ADRC patients and 3/14 (21.4%) of placebo patients. Two fatal events were reported during the trial with both occurring in the Cytori Cell Therapy group (myocardial ischemia – day 2 post-procedure, decompensation of heart failure – day 291 post-procedure).

Cytori ATHENA Trial for Chronic Ischemic Cardiovascular Disease | wallstreet-online.de - Vollständiger Artikel unter:
http://www.wallstreet-online.de/nachricht/8716972-cytori-ath…

http://onlinelibrary.wiley.com/doi/10.1002/ccd.26601/epdf?r3…

[Shanghai2006]

http://finance.yahoo.com/news/cytori-cell-therapy-phase-tria…

Cytori Therapeutics, Inc. (CYTX) announced today the publication of the results from an investigator-initiated Phase I trial using Cytori Cell Therapy in patients with insufficient maxillary bone prior to dental implantation. The publication reported approximately 42% greater bone formation in maxillary sinus floor elevation (MSFE) procedures treated with cells in combination with scaffolds versus those that received scaffold alone.

The study, conducted by investigators from Departments of Orthopedic Surgery, Oral and Maxillofacial Surgery, and Oral Cell Biology of the VU University in Amsterdam, The Netherlands, enrolled 10 patients requiring dental implants but who had insufficient bone into which the implant could be inserted. The maxillary bone deficiency was treated with two different commonly-used, off-the-shelf bone calcium phosphate scaffolds that were used either alone or pre-loaded with Adipose-Derived Regenerative Cells (ADRCs) prepared using Cytori’s Celution™ System. In six patients, the patient served as their own control as one side of the mouth was treated with scaffold alone and the other side was treated with ADRC-supplemented grafts. Six months after treatment all patients underwent dental implant placement at which time a biopsy of the regenerated bone at the graft site was performed.

The trial results reported approximately 42% greater bone formation in grafts that were supplemented with ADRCs. Specifically, in patients who received both a control scaffold and a contralateral ADRC- supplemented scaffold, the ratio of bone volume to total graft volume as measured by micro computerized tomography (microCT) was 19.5% ± 3.8% in grafts supplemented with ADRCs versus 13.7% ± 4.4% for the control grafts (p = 0.03). A similar trend was seen by histologic assessment of biopsies. They also noted that all 10 patients were treated uneventfully, with no adverse effects reported or detected in a large set of safety parameters through ≥3 years of follow-up.

Regarding the findings, the authors stated: “A striking observation from the histomorphometric and micro-CT analyses was the active bone formation observed at the cranial side of the biopsies in 7 out of 10 of the selected bone biopsies taken from the study [ADRC-treated] side, but only in 1 case from the control side. To our knowledge, this phenomenon has never been described before and may be unique to the current set-up.”

The American Academy of Implant Dentistry reports that approximately 500,000 patients receive dental implant surgeries in the USA every year. A recent report estimated that the global market for dental implants is projected to reach $5.8 billion by 2022. Use of calcium phosphate scaffolds for bone repair and reconstruction is also common in orthopaedic surgery.

The paper is titled: “Bone Regeneration Using the Freshly Isolated Autologous Stromal Vascular Fraction of Adipose Tissue in Combination With Calcium Phosphate Ceramics” published in the journal Stem Cells Translational Medicine. A link to the abstract can be found here. A full copy can be obtained without charge by registering with the publisher.

[Shanghai2006]

Cytori Therapeutics, Inc. (CYTX) will provide a live webcast of its second quarter financial results and business update on Thursday, August 4, 2016 at 5:30 PM Eastern Time.

The dial-in information is as follows:

Dial-In Number: +1.877.402.3914
Conference ID: 54687177

Prior to the webcast at approximately 4:15 PM Eastern Time on August 4, Cytori will issue its second quarter earnings release which will review Cytori’s second quarter performance. The webcast will be available both live and by replay two hours after the call in the “Webcasts” section of the company’s investor relations website.

http://finance.yahoo.com/news/cytori-cell-therapy-phase-tria…

[Shanghai2006]

Das heisst fuer mich. Jetzt nachkaufen.

[Merton75]

Antwort auf Beitrag Nr.: 52.901.089 von Shanghai2006 am 24.07.16 08:48:21

Zitat von Shanghai2006: Das heisst fuer mich. Jetzt nachkaufen.

Definitiv - gibt ja Millionen fundamentale Gründe dies zu tun

[Shanghai2006]

5.Aug.2016

Cytori Reports Second Quarter 2016 Business and Financial Results

http://finance.yahoo.com/news/cytori-reports-second-quarter-… (at the end is the balance sheet)

Cytori Therapeutics (CYTX) (“Cytori” or the “Company”) today announced its second quarter financial results and provided updates on its corporate activity and clinical development. Second quarter 2016 net loss allocable to common stockholders was $6.4 million and $0.43 per share. Cytori continues to tightly manage its operating cash burn, spending approximately $5.7 million in the second quarter 2016. Cytori ended the second quarter of 2016 with $20 million of cash and cash equivalents. “In the first half of the year, our team has advanced our development pipeline in the U.S. in multiple indications, most notably completing enrollment in our Phase 3 trial in scleroderma. Additionally, investigator-initiated studies are progressing in Europe and Japan, and we have continued to lay a sound foundation for early clinical adoption and profitable revenue growth in Japan and Europe, which can provide near-term revenue and importantly build longer-term strategic value,” said Dr. Marc H. Hedrick, President and Chief Executive Officer for Cytori. “Corporate milestones over the next twelve months include the first readout from our US phase III scleroderma trial in mid-2017, the initiation of an externally funded clinical trial in burn patients later this year, treatment of the first scleroderma patients as part of our compassionate use program, and Japanese revenue growth.” Select Recent Highlights: • Enrollment completion of US STAR phase III trial for scleroderma hand dysfunction • Report of 48-week US pilot/phase IIb ACT-OA trial preliminary topline data • Limited regulatory approval received by a Cytori customer regarding use of Cytori® Cell Therapy™ for osteoarthritis of the knee at its clinics in Japan • Completion of rights offering for gross proceeds of $17.1 million • Broad orphan drug designation granted by European Commission, and small or medium-size enterprise (SME) status granted by European Medicines Agency Q2 and Year-to-date 2016 Financial Performance • Q2 2016 and year-to-date operating cash burn of $5.6 million and $10.7 million, compared to $4.8 million and $9.8 million for the same periods in 2015, respectively. • Cash and debt principal balances at June 30, 2016 of approximately $20 million and $17.7 million, respectively. • Q2 2016 and year-to-date total revenues of $2.8 million and $5.7 million, compared to $3.5 million and $5.8 million for the same periods in 2015, respectively. • Q2 2016 net loss allocable to common stockholders of $6.4 million or $0.43 per share, compared to a net income of $4.5 million or $0.45 per share (or a net loss of $8.7 million and $0.94 per share when excluding a non-cash credit charge of $13.1 million related to the change in fair value of warrant liabilities) for the same period in 2015. • Year-to-date net loss allocable to common stockholders of $11.7 million or $0.84 per share, compared to $18.2 million or $2.22 per share (or a net loss of $15.2 million or $1.86 per share, which excludes a non-cash charge of $2.3 million related to the change in fair value of warrant liabilities and a beneficial conversion feature charge for convertible preferred stock of $0.7 million) for the same period in 2015. “We reduced our net losses by over 25% from Q2’15 to Q2’16, despite substantial development progress that includes completion of enrollment in our U.S. Phase III scleroderma trial,” said Tiago Girao, VP of Finance and CFO of Cytori Therapeutics. “Our current projections indicate that the net proceeds from our Q2 financing activities coupled with ongoing downward pressure on expenses coupled with revenue growth, will provide liquidity for at least the next 12 months of operations.” Summary of ACT-OA trial and topline 48-week results: The ACT-OA trial was a randomized double blind phase II trial comparing a single administration of either low or high doses of ECCO-50 autologous cellular therapeutic placed into the intraarticular space of one knee in 94 patients with knee osteoarthritis of moderate severity. This pilot trial was designed to establish safety, feasibility and explore a number of efficacy endpoints for a more definitive trial with appropriate statistical powering. Topline results concluded: • Intraarticular application of a single dose of ECCO-50 is feasible in an outpatient day-surgery setting; no serious adverse events were reported related to the fat harvest, cell injection or to the cell therapy. • Consistent trends observed in most secondary endpoints at 12, 24 and 48 weeks in the target knee of the treated group relative to placebo control group; as reported in Q1, 12 week primary endpoint of single pain on walking question did not achieve statistical significance. • Consistent trends observed in all 6 pre-specified MRI Osteoarthritis Knee Score (MOAKS) classification scores suggesting decrease in target knee joint pathologic features at 48 weeks for the treated group relative to placebo control group. “The safety and feasibility goal of this first trial in OA was substantially achieved,” said Dr. Mark Marino, Cytori Senior Vice President of Clinical Affairs. “Additionally, even though this first randomized controlled trial was not statistically powered to test for a specific therapeutic hypothesis, it showed evidence of a potential cell effect including in the joint imaging data. Further analysis is ongoing on specific patient subsets and in-depth anatomic assessment of the MRI data.” Anticipated Forthcoming Milestones: • Clarity for European Union Conditional Market Approval in scleroderma hand dysfunction • File IDE and obtain approval for burn wound therapy trial related to contract with BARDA (anticipated in 2016) • Report of 48-week US pivotal/phase III trial data for scleroderma hand dysfunction 2016 Reiterated Financial Guidance • Operating cash burn within a range of $18 million to $20 million • Total revenues (product and contract) within a range of $12 million to $14 million Management Conference Call Webcast Cytori will host a management conference call at 5:30 p.m. Eastern Time today to further discuss the Company's progress. The webcast will be available live and by replay two hours after the call and may be accessed under "Webcasts" in the Investor Relations section of Cytori's website. If you are unable to access the webcast, you may dial in to the call at +1.877.402.3914, Conference ID: 54687177.

[Hubertuss]

Na sehr schön, hier tut sich ja auch nichts!

Gruß

[Hubertuss]

FDA approves Cytori's burn clinical trial related to BARDA contract; shares ahead 23% premarket

Apr. 10, 2017 7:34 AM ET|About: Cytori Therapeutics Inc (CYTX)|By: Mamta Mayani, SA News Editor
Cytori Therapeutics (CYTX) announces that the FDA has approved an Investigational Device Exemption (IDE) for a pilot clinical trial to evaluate Cytori Cell Therapy in patients with thermal burn injury.

This trial, named the RELIEF trial, is a continuation of Cytori’s ongoing R&D efforts under its contract with the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services.

The RELIEF trial will assess safety and feasibility of intravenous delivery of Cytori Cell Therapy in patients with thermal burn injuries covering between 20% and 50% of their body surface area. The trial is approved to enroll up to 30 patients in up to 10 U.S. sites. Initiation of RELIEF is dependent upon execution of a contract option by BARDA to provide the necessary funds.

Shares are up 23% premarket.



o.k., da kommt dann doch ein wenig Freude auf, mal schauen!
Gruß

[Merton75]

Antwort auf Beitrag Nr.: 54.710.640 von Hubertuss am 10.04.17 16:24:15

Ich schreibe das SEIT 7 JAHREN!

Dieser Betrug hier ist ein Zusamenschluss von
Management (CYTX)
"Prüfungsgesellschaft" Bdo..usw..
SEC
Analysten bzw. "Broker" wie Maxim
Hedgefonds (SABBY)
..

Die Jungs lachen Euch aus und keiner kontrolliert das

Gestern wurde eine "FDA Meldung" herausgegeben - Aktie springt auf 2$ und alle laden ab.
Dann bringt "das Management" eine Meldung heraus das Aktien geflutet werden und der Kurs halbiert sich mit 100k Aktien (nach 16 Millionen vorher die "durchgehandelt" wurden)..
Dazu die short ratio etc..
Zudem wurde ja vor ein paar Wochen shon über 6m Aktien rausgegeben.. ZUFALL??

Die Jungs haben gestern und heute wieder mit abgesprochenen Meldungen Millionen gemacht und jeder bekommt seinen Anteil - außer ein Investor

Das ist alles so offensichtlich und daher muss man sich fragen warum die SEC sowas "übersieht"

Das filling gestern war ohne KURS oder Datum - Nur auf Grundlage das cytx über 2$ gesprungen ist und die Jungs wieder drücken wollten auf 1$ (nun wieder 100% um auf 2..)

[Merton75]

Antwort auf Beitrag Nr.: 54.720.024 von Merton75 am 11.04.17 19:35:27

Jetzt beginnt das Spiel wieder von neuem.
Vor einem Jahr war es ein 1-15 Split.. Danach wurden Aktien geflutet und die HF haben untereinander den Kurs festgelegt.
Letzt Woche als der Kurs dann mal wieder über 2 war dachten die Kollegen sich - warum nicht wieder Aktien fluten und den HF die Aktien für die Hälfte (also 1) geben? Die SEC hat das ganze unterstützt indem dann das filling ohne Angaben akzeptiert wurde.
Jetzt bricht der Kurs wieder bis auf 20 Cent zusammen und dann wird wieder 1-15 gesplittet und das Spiel beginnt neu..
Jeder kann es sehen und ohne Schmiergeld würde es auch nicht laufen. Daher immer schön aufpassen denn regulatorische Revisionen kann man theoretisch nur erahnen.

[Merton75]

Antwort auf Beitrag Nr.: 54.874.777 von Merton75 am 05.05.17 16:11:33

Gewinn letzte Woche für die HF war - 16 Millionen mal 2 Dollar = 32m Dollar (vielleicht etwas weniger wenn noch andere gehandelt haben).
Diese Aktien haben die Jungs Wochen vorher fast geschenkt bekommen und dann damit geflutet.
Der Rest wird short geholt und könnte jetzt bspw. für die Hälfte zurückgeholt werden.
Alles in allem sind 20-30m Dollar in ner Woche ne gute Sache für die Jungs wenn man bedenkt das die Bude nichtmal soviel "wert ist"

[Merton75]

Antwort auf Beitrag Nr.: 54.874.789 von Merton75 am 05.05.17 16:13:43

Man beachte auch die Startegie bzw. Aktienzahl
JETZT reichen 40T Aktien für 10% Minus (beudetet 40T/15 = 2.66T Aktien vorher).. Also ca. 2Tausend Dollar Einsatz.. (für 20-30 Millionen Ertrag)
Im Grunde wird der Betrug immer günstiger und an ein paar Tagen im Jahr wird mit der SEC und den HF zusammen abgeräumt..

[Shanghai2006]

SAN DIEGO, Calif., May 23, 2017 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (CYTX) ("Cytori" or the "Company"), today announced that it has now completed all 48 week follow up monitoring visits in its U.S. FDA approved Phase III STAR trial. A total of 88 subjects were enrolled and the last subject’s 48 week visit was conducted earlier this week.
STAR is a double-blind, randomized, placebo-controlled, parallel group phase III pivotal study investigating the efficacy and safety of HABEO™ Cell Therapy™on subjects with impaired hand function from scleroderma. The subjects were randomized 1:1 to either HABEO Cell Therapy or placebo. HABEO™ and placebo were administered subcutaneously in subject’s fingers. Final assessments were done at 48 weeks.  Upon unblinding and evaluation of the data, subjects who received placebo will be offered participation into the crossover portion of the protocol, using HABEO™ Cell Therapy™, should they desire treatment and continue to qualify. Details of the STAR trial including inclusion and exclusion criteria can be found at the following link: clinicaltrials.gov
In the United States, the scleroderma affected population appears to be approximately 184 per million, which would represent a market size of aproximately 45,000 scleroderma patients.1 Additionally, in Europe, scleroderma is estimated to have a prevalence between 31 per million and 277 per million which equates to approximately 17,000 to 149,000 scleroderma affected people in the Europe.

https://finance.yahoo.com/news/cytori-logs-final-48-week-123…

[Shanghai2006]

Good link for patents updated weekly

http://stks.freshpatents.com/Cytori-Therapeutics-Inc-nm1.php

[Shanghai2006]

Cytori and BARDA Execute $13.4 Million Contract Option for Burn Clinical Trial

SAN DIEGO, May 31, 2017 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) (“Cytori” or the “Company”) today announced that the Company and the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response (ASPR), have executed a contract option valued at approximately $13.4 million.

The executed option will fund the Company’s RELIEF trial, a U.S. pilot clinical trial of Cytori Cell Therapy™ (DCCT-10) in thermal burn injury as the next step in development of Cytori technology as a medical countermeasure for thermal burn injury. The present option increases the overall BARDA commitment to Cytori technology to approximately $34.6 million thus far.

Patients with large burns frequently require treatment with an autologous skin graft. Unpublished preclinical data generated by Cytori under its BARDA-funded development program indicate that intravenous delivery of Cytori Cell Therapy was associated with increased formation of new skin (epithelialization) and earlier restoration of the barrier function of the newly-formed skin1. The RELIEF trial will apply the same approach in the clinic.

“Cytori continues to develop Cytori Cell Therapy technology as a multiuse platform for use in both the routine clinical setting and in the event of a mass casualty emergency,” said Dr. Marc Hedrick, President and Chief Executive Officer of Cytori. “There are several published reports indicating clinical benefit of Cytori Cell Therapy in chronic wound healing. This trial provides Cytori the opportunity to extend these reports by assessing utility of intravenous administration in an acute traumatic situation.” 2

The RELIEF trial will assess safety and feasibility of intravenous delivery of Cytori Cell Therapy™ as an adjunct to usual care in patients with thermal burn injuries covering between 20% and 50% of their body surface area. Subjects will have at least one deep partial or full thickness burn wound that is to be treated with a meshed autologous split thickness skin graft (STSG). Subjects will be randomized (1:2) to receive either usual care alone or usual care supplemented with Cytori Cell Therapy. While primarily focusing on safety and feasibility, the RELIEF trial will also assess a series of parameters related to skin graft healing. The trial is approved to enroll up to 30 patients in up to 10 U.S. sites with study initiation expected to occur in Q4 2017.

This project with BARDA was initiated to evaluate Cytori Cell Therapy as a potential medical countermeasure that could be used to treat thousands of patients with a combination of burn and radiation injury following detonation of an improvised nuclear device in a major USA metropolitan area. The first step towards achievement of this goal was completed in pre-clinical studies which reported that intravenous delivery of Cytori Cell Therapy improved healing of full thickness burn wounds complicated by radiation injury (linked here).

The RELIEF clinical trial represents the next step in this path. The original contract with BARDA retains two as-yet unfunded options valued at up to $68 million. The first of these options is written to support a pivotal clinical trial that could potentially follow RELIEF and lead to FDA approval of Cytori Cell Therapy as a treatment for thermal burn injury. The second option addresses additional preclinical work targeting application in thermal burn and radiation injury.

BARDA is developing medical countermeasures for use following a mass casualty disaster involving burns to address the ill-preparedness of the current healthcare system to deal with very large numbers of patients requiring treatment for thermal burns, particularly those complicated by concomitant radiation exposure. According to the American Burn Association, there were approximately 450,000 burn injuries in 2013 that required medical treatment in the United States, with approximately 40,000 requiring hospitalization. In a mass casualty event, the Government Accountability Office estimates that as many as 10,000 patients could require thermal burn care. The limited number of specialist surgeons and burn centers in the U.S. creates a public health need for a burn wound therapy that can be quickly and broadly applied by non-specialist medical personnel following such an event. Current standard of care for large burns consists of dressings, skin grafts and skin substitutes. Despite these treatments, patients with severe burns commonly suffer from prolonged pain, aggressive scarring, skin contracture and reduced range of motion. Cellular therapeutics such as those offered by Cytori may have the potential to improve the quality and rate of wound healing and reduce scarring and also can be deployed in a cost effective manner, even in mass casualty situations.

1. Data from Cytori Study

2. Published reports of use of Cytori Cell Therapy™ in chronic wounds include, but are not limited to:

•Akita et al (2012) Radiat Prot Dosimetry 151 (4): 656-660

•Cervelli et al (2011) Stem Cell Res 6 (2) 103-11
•Daumas et al (2016) Curr Res Trans Med 65 (1) 40-43
•Mizushima et al (2016) Surg Today 46 (7) pp. 835-42
•Iddins et al (2016) Health Phys. 111(2):112–116; 2016

About Cytori Therapeutics, Inc.

Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. Cytori Nanomedicine™ is developing encapsulated therapies for regenerative medicine and oncologic indications. For more information, visit www.cytori.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, statements regarding Cytori’s use of BARDA funding; the possibility that pilot trial costs exceed the BARDA funding (in which case Cytori will be responsible for such costs); conduct of the RELIEF clinical trial; potential benefits of Cytori Cell Therapy™ (including its potential cost and clinical benefits, and its future availability as a medical countermeasure for thermal burn injury); potential patient populations requiring thermal burn care; and potential additional BARDA funding of Cytori’s development program, are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include: a possible adverse decision by BARDA to delay, suspend or reduce funding of Cytori’s proposed RELIEF clinical trial or other development efforts under its contract with BARDA or other changes in BARDA’s funding and procurement priorities that may adversely affect our thermal burn injury program; BARDA’s sole discretion in determining funding timing and amounts; BARDA’s ability to reduce, modify or terminate its contract (and contract options) with us if it determines it is in the government’s best interests to do so; the risk that Cytori is unable to complete development work necessary to receive BARDA funding; the risks that quality of data supporting IDE approval and execution of BARDA contract options is deemed insufficient; risks in the collection and results of clinical data; risks associated with final clinical outcomes; regulatory risks and uncertainties; risks related to dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" section in Cytori's Securities and Exchange Commission Filings on Form 10-K and Form 10-Q. Cytori assumes no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends or circumstances after the date of this communication.
Cytori Therapeutics, Inc.

http://ir.cytori.com/investor-relations/news/news-details/20…

[Shanghai2006]

Cytori to Introduce Next-Generation Celution® Technology

SAN DIEGO, June 01, 2017 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) ("Cytori" or the "Company"), today announced plans to introduce its next-generation Celution® technology. The technology is available for pre-orders effective June 1st, 2017 with first product shipments anticipated to begin in Q3.

The next-generation Celution® technology incorporates new hardware and enhanced software that substantially improves performance and maintains compliance with evolving global medical device and cell therapy standards. Cytori will offer the new technology through chargeable upgrades to its existing global Celution® user base (where available) and as a standard feature set for Celution® Systems purchased by new customers.

“Cytori continues to evolve its technology platforms as it simultaneously advances its clinical programs,” said John Harris, Vice President and General Manager of Cell Therapy. “This new technology, partially supported through our BARDA contract, will be the cornerstone of our U.S. RELIEF clinical trial for thermal burn injuries and potential U.S. FDA PMA submission for Habeo™ Cell Therapy for scleroderma-associated hand dysfunction.”

This next-generation technology builds on nearly a decade of market experience, thousands of single-use procedure sets sold, numerous clinical trials and our most recent research and development activities.

“This announcement marks the most significant new evolution of our cell therapy technology in years,” said Russ Havranek, Vice President, Global Marketing at Cytori. “This enhanced product offering should immediately resonate with our current installed base in a variety of countries and potential new customers interested in clinical cell therapy for reconstructive, aesthetic and orthopedic conditions.”

https://finance.yahoo.com/news/cytori-introduce-next-generat…

[Shanghai2006]

6/8/2017 7:34 AM ET

Cytori Therapeutics, Inc. (CYTX), a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy, on Thursday reported patient satisfaction and surveillance for cancer recurrences following use of Cytori Cell Therapy for breast reconstruction following partial mastectomy and radiation for breast cancer treatment.
The company announced the publication of long-term follow-up data on Cytori Technology.
This Cytori-supported, investigator-initiated study, which was peer-reviewed and published in June 2017 edition of Surgery Today, followed ten patients treated with a single therapeutic administration of Cytori Cell Therapy at Kyushu University. None of the ten patients experienced cancer recurrence or new cancer formation through a median of 8.5 years of follow up.

Scarring and tissue volume loss, particularly following extirpative surgery and adjuvant radiation therapy remains a significant reconstructive problem for survivors of breast cancer. Cytori's technology is available to doctors in Japan under the new regenerative medicine regulations for reconstructive purposes.
The company noted that several pre-clinical and clinical studies suggest that Cytori Cell Therapy has potential to help alter markers and outcomes related to fibrosis characterized by tissue fibrosis, irrespective of the etiology of the fibrosis.

Currently, there are three ongoing clinical trials involving Cytori Cell Therapy in which fibrosis is an important pathophysiologic feature of the primary disease.

http://www.rttnews.com/2782639/cytori-publishes-long-term-sa…

[Shanghai2006]

Financial report 30 March 2017

http://www.capitalcube.com/blog/index.php/cytori-therapeutic…

[Shanghai2006]

Cytori® Partners with myTomorrows for Managed Access Program for Europe, Middle East and Latin America

Jun 14, 2017

Partnership to Launch at the EULAR (European League Against Rheumatism) Congress in Madrid, Spain June 14-17

SAN DIEGO, June 14, 2017 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) ("Cytori" or the "Company"), announces its new managed access program partnership with myTomorrows at the European League Against Rheumatism (EULAR) Congress in Madrid, Spain between June 14 and 17. Cytori and myTomorrows share the goal of providing early and ethical access to Cytori’s Habeo Cell Therapy™ to patients in Europe, Middle East and Latin America.


“Providing compliant access to patients who may benefit from therapies in clinical development is the objective of Managed Access Programs (MAP). Habeo Cell Therapy fits the defined parameters of a MAP-eligible therapy. Towards that end, Cytori is excited to leverage myTomorrow’s expertise and expanded scope to take our MAP in a new direction,” said John Harris, Vice President and General Manager at Cytori. “We look forward to kicking off our relationship at the EULAR congress in Madrid, Spain this week.”

myTomorrows is an innovative and fully integrated organization dedicated to providing fully compliant early access to innovative therapeutics in advance of the products full marketing authorization in the countries that it serves. myTomorrows will serve as Cytori’s exclusive MAP for patients with scleroderma-associated hand dysfunction. myTomorrows will leverage its footprint to provide patients early access to Habeo Cell Therapy for the Middle East and Latin America in addition to Europe.

“The opportunity to collaborate with Cytori to lend support to patients in need is exactly in line with our team’s mission and core competences,” said Govert Schouten, Co-Founder and Chief Business Officer at myTomorrows.

The EULAR Congress is considered to be a major event in the global rheumatology network and seeks to serve as a platform to facilitate interactions between patients, medical doctors, scientists, health professionals and industry surrounding scientific and clinical information. Cytori Therapeutics’ booth is #47 in the main congress hall, where we will highlight the STAR and SCLERADEC-II clinical trials that are currently in progress in the U.S. and France, respectively. Representatives will be available to answer questions about the Habeo Cell Therapy Managed Access Program.

myTomorrows will be responsible for the design, implementation, and performance of the Managed Access Program and their Netherlands-headquartered and field-based teams will apply their knowledge and expertise toward physician and patient support, legal and regulatory administration, pharmacovigilance, logistics, and data collection.

http://ir.cytori.com/investor-relations/news/news-details/20…

[Shanghai2006]

SAN DIEGO, July 10, 2017 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (CYTX) announced today that the American Medical Association’s (AMA) CPT® (Current Procedural Terminology) Editorial Panel has approved the company’s request to add two new Category III CPT codes that describe a cell-based therapy for patients with scleroderma of the hands. These codes have been published on the AMA website and will be effective January 1, 2018.
The AMA’s CPT® Editorial Panel creates Category III CPT codes to describe new and emerging healthcare technology, services, and procedures.  Cytori worked with the American College of Rheumatology, the American Society of Plastic Surgeons, and the American Society for Surgery of the Hand to prepare the requests and received approval for the following Category III CPT codes:
0489T, for autologous adipose-derived regenerative cell (ADRC) therapy for scleroderma in the hands; adipose tissue harvesting, isolation and preparation of harvested cells including incubation with cell dissociation enzymes, removal of non-viable cells and debris, determination of concentration and dilution of regenerative cells
0490T, for autologous ADRC therapy for scleroderma in the hands; multiple injections in one or both hands
“We applaud the Editorial Panel’s approval of these two new CPT codes, as it marks the essential first step in enabling physician and facility access to our investigational Habeo™ Cell Therapy in the U.S.,” said Russ Havranek, Vice President, Global Marketing at Cytori. “We are also thankful for the support provided by the medical specialty societies in helping us achieve this important milestone.” 
Cytori is currently conducting the U.S. Phase III pivotal STAR trial, a randomized, double-blind, placebo-controlled, parallel-group, multi-center study investigating the safety and efficacy of Habeo™ Cell Therapy in patients with hand dysfunction due to scleroderma. STAR follows the 12-patient SCLERADEC-I trial, an open-label, single-arm, investigator-initiated study conducted in Marseille, France.  More information about STAR and SCLERADEC-I can be found on clinicaltrials.gov and sciencedirect.com, respectively.
“Scleroderma with hand dysfunction is an extremely debilitating disease, and yet patients historically have had very limited treatment options,” said Dinesh Khanna, M.D., M.S., the Frederick G.L. Huetwell Professor of Rheumatology, Professor of Internal Medicine, and Director of the Scleroderma Program at the University of Michigan, and principal investigator in the Phase III STAR trial of Habeo™ Cell Therapy in patients with hand dysfunction due to scleroderma. “Habeo™ Cell Therapy is a novel treatment with the potential to make a significant impact in these patients’ lives.  I am encouraged by the clinical evidence generated to date and look forward to reviewing the STAR 48-week results.”
“The codes approved by the Panel accurately describe Habeo™ Cell Therapy,” said STAR investigator Mark Granick, M.D., Professor of Surgery and Chief of Plastic Surgery in the Department of Surgery at Rutgers New Jersey Medical School. “The use of ADRCs for treating scleroderma related hand dysfunction requires far more specificity and effort than the more commonly performed liposuction or fat grafting procedures.  The injection of the ADRC solution into the fingers similarly is a highly specialized process requiring a familiarity with hand anatomy and surgery.”

https://finance.yahoo.com/news/american-medical-association-…

[Shanghai2006]

SAN DIEGO, July 06, 2017 (GLOBE NEWSWIRE) --  Cytori Therapeutics, Inc. (NASDAQ:CYTX) (“Cytori” or the “Company”) announced today the issuance of key patents that strengthen its intellectual property portfolio in the U.S. and Europe. Cytori now has 107 global patents issued and another 45 patent applications pending around the globe. Several of Cytori’s recently issued patents contain claims covering the use of Habeo™ Cell Therapy for patients with scleroderma affecting the hands.
On July 5, 2017 the European Patent Office (EPO) issued Patent No. 3046417, which claims the use of Adipose-Derived Regenerative Cells (ADRCs), including Cytori’s Habeo™ Cell Therapy for  scleroderma, including treatment of Raynaud’s Phenomenon or suppression of pain from Raynaud’s Phenomenon.  This patent has a term at least through 2034. 
On April 19, 2017, the EPO issued Patent No. 1670315, which claims the use of ADRCs, including Cytori’s Habeo™ Cell Therapy, to treat vascular diseases, which are disorders that affect the blood carrying vessels of the body. Vascular disease is a very common complication in patients with scleroderma where it can contribute to digital ulcers and other problems. This patent has a term at least through 2024 and covers the use of Habeo™ Cell Therapy for vascular diseases, including but not limited to disease associated with scleroderma.
On December 6, 2016, the U.S. Patent Office issued Patent No. 9511096, which claims the use of ADRCs, including Cytori Cell Therapy™, to treat ischemic wounds. This patent has a term at least through December 2022 and covers the use of Habeo™ Cell Therapy for treatment of digital ulcers in scleroderma patients. 
"Building on Cytori’s broad intellectual property portfolio continues to be a priority," said John D. Harris, Vice President and General Manager, Cell Therapy. "Our intellectual property strategy is to continue to strengthen the Cytori Cell Therapy™ platform  to help establish and maintain a sustainable competitive advantage. Our main focus is on the primary therapeutic targets of scleroderma and Raynaud’s Phenomenon, though we will continue to seek additional intellectual property in other therapeutic areas as well."

http://ir.cytori.com/investor-relations/news/news-details/20…

[Shanghai2006]

SAN DIEGO, Jul 24, 2017 (GLOBE NEWSWIRE via COMTEX) --
Statistical significance not achieved in primary or secondary efficacy endpoints
Clinically meaningful efficacy trends observed in primary and secondary endpoints in pre-specified diffuse cutaneous scleroderma subgroup
No significant safety related issues
Conference call scheduled for 8:30am EDT
Cytori Therapeutics, Inc. CYTX, +0.02% today announced top-line, preliminary data from its pivotal STAR trial of Habeo [TM] Cell Therapy in patients with scleroderma. While the primary endpoint, Cochin Hand Function Score (CHFS), did not reach statistical significance at 24 or 48 weeks, the trial data reported clinically meaningful improvements in the primary and secondary endpoints of both hand function and scleroderma-associated functional disability, for Habeo treated patients compared to placebo, in a subgroup of patients with diffuse cutaneous scleroderma.
The U.S. multi-center STAR trial enrolled and evaluated 88 patients with scleroderma, including 51 patients within the diffuse cutaneous subset and 37 with limited cutaneous scleroderma. In the combined study population, the primary endpoint, specifically mean improvement in the Cochin Hand Function Score, did not show statistical difference between treated patients and those receiving placebo at 24 weeks and 48 weeks as determined by both analysis of covariance and mixed model repeated measure analysis.
The Raynaud's Condition Score, a secondary endpoint, improved in both the treatment and placebo group but was not statistically different between the Habeo treated and placebo groups.
However, in the pre-specified subgroup analysis of patients with diffuse cutaneous scleroderma, a more severe form of the disease, improvements in the Cochin Hand Function Score and the Health Assessment Questionnaire-Disability Index (HAQ-DI), a measure of functional disability and an important secondary endpoint, met or exceeded the published criteria for minimally important clinical differences in these measures (6.5 points for Cochin [1] , 0.22 points for HAQ-DI [2] ).

+ Analysis of co variance using ANCOVA mean changes from baseline.
  
+ Mixed model repeated measure analysis, MMRM mean changes from baseline.
  
"The safety and efficacy results from this trial in the diffuse subset of patients with scleroderma are impressive and represent important new information for the field," said Dinesh Khanna, MD, Frederick G.L. Huetwell Professor of Medicine and Director of the University of Michigan Scleroderma Program. "The STAR trial suggests that Habeo may provide clinically meaningful improvements in the hand function and functional disability to patients with diffuse form of the disease who have no other treatment options. The diffuse subset has a more severe disease burden with significant hand dysfunction and internal organ involvement as well as the highest mortality rate among all rheumatic diseases. It is important for these patients that this innovative technology moves forward in the clinical and regulatory process."

"We are disappointed that the study missed the primary and secondary endpoints. However, we are very encouraged by the trends toward improved hand function and scleroderma-related health status in patients with diffuse cutaneous scleroderma," said Marc H. Hedrick, MD, President and Chief Executive Officer of Cytori Therapeutics, Inc. "We thank the STAR investigators and patients for participating in this trial, which has yielded new insights into scleroderma and shows yet again that discrete patient populations may respond differently to investigational therapies - an important consideration for individuals currently lacking treatment options for rare diseases. After we review the complete data set, we will work collaboratively with our team, trial investigators, patient advocates and the regulatory bodies in our key markets, to chart the next steps for this therapy."
In general, the adverse events were rated as mild to moderate in the majority of cases and there were no significant safety issues identified for Habeo or the procedure itself (including liposuction and finger injection in the placebo group) during the trial.
"We are pleased with both the efficacy trends as well as the safety profile of Habeo," said Dr. Mark Marino, MD, Senior Vice President and Chief Medical Officer of Cytori Therapeutics, Inc. "Following the evaluation of the full STAR data set, Cytori, in conjunction with the investigators, intends to submit the full data set, as a late-breaking abstract, to the American College of Rheumatology meeting in November 3-8, 2017. Simultaneously, we anticipate seeking a post-trial meeting with FDA as soon as possible to define next steps. We further plan to continue to support the investigator-initiated SCLERADEC-II trial in France, which is over 50 percent enrolled."
Management Conference Call Webcast Cytori will host a management conference call at 8:30 a.m. Eastern Time today to further discuss the preliminary top-line results from the STAR trial. The webcast will be available live and by replay two hours after the call and may be accessed under "Webcasts" in the Investor Relations section of Cytori's website. If you are unable to access the webcast, you may dial in to the call at +1.877.402.3914, Conference ID: 60408495.
About STAR The STAR trial was a prospective, double-blind, randomized, multicenter, parallel-group Phase III pivotal study assessing the safety and efficacy of a single, subcutaneous administration of Habeo Cell Therapy (40 million cells per subject) into the fingers of patients with hand dysfunction due to scleroderma. The subjects were randomized 1:1 to receive either Habeo Cell Therapy or placebo. Investigators conducted final assessments at 48 weeks.
The primary study endpoint was improvement in the Cochin Hand Function Score, a self-reported measure of hand function, which was assessed at 24 and 48 weeks. The Cochin score is based on 18 questions relating to hand function; each question is graded on a 0-5 scale, with a total score of 90 points reflecting maximal disability.
The Health Assessment Questionnaire-Disability Index (HAQ-DI), a measure of functional disability and a secondary endpoint in the STAR trial, consists of questions pertaining to activities of daily living graded on a 0-3 scale (with 3 representing "unable to perform"); the HAQ-DI also includes several visual analog scales (VAS) for different body systems.
The Raynaud's Phenomenon Condition Score, a secondary endpoint in the STAR trial, is a patient reported outcome measure asking the patients how much difficulty they had with their Raynaud's symptoms over the past 24 hours graded on a scale of 0 - 10 with 0 being no difficulty and 10 being extreme difficulty.
Details of the STAR trial, including inclusion and exclusion criteria, can be found at clinicaltrials.gov.
About Scleroderma Scleroderma is a rare and chronic connective tissue disease generally classified as an autoimmune rheumatic disorder. The word "scleroderma" is derived from two Greek words: "sclera," which means hard, and "derma," meaning skin, as hardening of the skin is one of the most visible manifestations of the disease. An estimated 300,000 Americans have scleroderma, about one-third of whom have the systemic form of the disease, known as systemic sclerosis (SSc). SSc is further sub-classified as diffuse cutaneous and limited cutaneous SSc. Patients with diffuse cutaneous SSc have more severe disease with significant hand dysfunction and internal organ involvement. Diffuse scleroderma accounts for between one-third and one-half of all cases of systemic sclerosis. [3,4]
SSc contributes to hand impairment through inflammatory arthritis or inflammation of the joints, joint contractures, Raynaud's Phenomenon (RP, skin discoloration resulting from narrowing of the blood vessels in response to cold, emotional upset, or stress), digital ulcers, puffy hands and skin fibrosis over the fingers and hands, and calcinosis (calcium deposits in the soft tissues of the hand). These manifestations, which often coexist, can contribute to difficulty with occupational activities and activities of daily living, which can impair quality of life. Whereas current treatment recommendations focus on management of internal organ involvement, there is little treatment available for hand impairment.
About SCLERADEC-II SCLERADEC-II is an investigator initiated, multicenter, double blind, placebo controlled trial of a single administration of Habeo Cell Therapy. The trial contemplates enrollment of up to 40 patients randomized in a 1:1 fashion to receive either active treatment or placebo control. The primary endpoint is the Cochin Hand Function Score at 3 months following treatment. Key secondary endpoints include Raynaud's Condition Score, HAQ-DI, pain, the modified Rodnan Skin Score, capillaroscopy and functional hand assessment. Patients receiving placebo will be eligible for cross-over to the active arm after 6 months with their respective cryopreserved cells.
About Habeo Cell Therapy Cytori is developing cell therapies that harness the unique attributes of adipose-derived regenerative cells (ADRCs), which are living cells that are present in an adult human's own adipose tissue.
Habeo Cell Therapy is a suspension of ADRCs that are manufactured from a single lipoaspirate (material removed via liposuction, a procedure in which fat is removed from under the skin by suction). The process concentrates ADRCs intended for autologous re-implantation subcutaneously into the digits. The resultant cell suspension contains critical cells naturally occurring in the patient's own tissue. Preparation of autologous ADRCs for subcutaneous delivery involves no cell culture and can be prepared and re-implanted into the same patient within four hours.

http://www.marketwatch.com/story/cytori-announces-top-line-2…

[Turnover15]

Antwort auf Beitrag Nr.: 55.388.610 von Shanghai2006 am 25.07.17 01:05:04

Statistical significance not achieved in primary or secondary efficacy endpoints = dead

[boyoboy]

Antwort auf Beitrag Nr.: 55.393.139 von Turnover15 am 26.07.17 08:46:22

"A History of Excellence"

"A History of Excellence"

Quelle: http://www.cytori.com/about/

Und die Cytori Fanseite ist auch schon tot.

http://www.junge-füchse.de/adhocs.htm

Wie sagte einst Kostolany:

"Ein Mann kann zwischen mehreren Methoden wählen, sein Vermögen loszuwerden: Am schnellsten geht es am Roulette-Tisch, am angenehmsten mit schönen Frauen und am dümmsten an der Börse."

[Merton75]

Antwort auf Beitrag Nr.: 55.413.272 von boyoboy am 28.07.17 15:35:44

Sollte sich ja rausfinden lassen wem die Seit(en) gehören und wer gepusht hat.
Zudem ist die Akquisition in 2017 in Kombination zu einer KE zu 1$ (bei einem Kurs von 2$) mehr als "dubios" bei gleichzeitigen Schulden inkl. einer Marketcap. von nun 15m$.. Bei einem Chapter 11 wird man sehen an wen das alles geht und ob der "Investor" an allem beteiligt war. (gibt jeden Jahr zig Bspw. und über Konten ließe sich das nachweisen, wenn man wollen würde)
Alles in allem ein Beweis das dies mehr ist als Roulette, da es hierbei wenigstens eine Überwachung gibt und man von einem legalen Spiel ausgehen kann...

[boyoboy]

Antwort auf Beitrag Nr.: 55.427.826 von Merton75 am 31.07.17 17:07:54

Deine Idee klingt gut, denn da stinkt vieles in diesem Laden. Meine Erfahrung ist, dass es nichts oder nur Brosamen bringt. Ich war an dem Wordcom Class Act beteiligt, von meinen Verlusten auf 2 Depots bekam ich etwa 1 Prozent zurück, verteilt über circa 10 bis 15 Scheck. Jeder Scheck kostete damals soweit ich weiß 15 Dollar Einlösegebühr. Zieht man die Scheckgebühren, Porti (per Einschreiben) und nicht zu vergessen die Arbeit ab, hat man draufgelegt.

Auch bei TFG/Vestcorp, Comroad und anderen meiner Depotleichen war kein Schadenersatz zu sehen.

[Merton75]

Antwort auf Beitrag Nr.: 55.428.213 von boyoboy am 31.07.17 17:51:36

Mir geht es hier in erster Linie darum das die Manipulatoren nicht in den Knast wandern.
Bspw. : https://www.thestreet.com/story/14249680/1/pharma-bro-martin… martin-shkreli hat selbst HIER manipuliert. Dazu sieht man es seit Jahren wie es passiert.
"Das Management" gibt zus. Falsche Infos raus und manipuliert Ergebnisse von Studien oder veröffentlicht diese erst Monate später (s. vor 2 Jahren). Dazu werden gezielte Infos mit den HF abgesprochen und der Kurs eingestampft, damit man sich dann die ganzen Patente usw. für weniger als n paar Dollar kaufen kann und dann ein neues Unternehmen aufmacht und die Nummer wieder durchzieht.
All das unter den Augen der SEC - was eigentlich das schlimmste ist aber zeigt das man besser in die staatlich überwachten Spielcasinos geht, da hier wenigstens eine Überwachung stattfindet..

Was hier über JAHRE abgezogen wurde ließe sich mit den An und Verkäufen plus Depotinhaber locker auswerte, wenn jmd Interesse daran hätte

[Shanghai2006]

Ne neue KE

https://www.sec.gov/Archives/edgar/data/1095981/000095012317…

[Merton75]

Antwort auf Beitrag Nr.: 55.528.629 von Shanghai2006 am 15.08.17 15:25:51

Das ist keine "normale KE", sondern eine Absprache zwischen "dem Unternehmen", den Hedgefonds und "weiteren Insidern" inkl. der SEC (Daher auch keine "Daten gefüllt" im SEC Filling)
Hier wird die komplette Marktkap. innerhalb eines Jahres mit Warrents verdoppelt (wie auch vorher wobei die Geschwidigkeit unfassbar ist).
Es gibt zwei Strategien - entweder die Jungs machen so weiter bis einer alle Aktien hat oder es wird so vor die Wand gefahren und einer übernimmt die Anteile.. Vorher wird mit Shorts Geld gemacht und Aktien gezielt verkauft
(Es ist auch kein Zufall das 11 Mill. Aktien nach einem Absturz von 60% kommen. Vorher hatte man auch bei 2$ absichtlich eine Meldung rausgebracht um eine KE zu 1$ durchführen zu können - am selben Tag ) - alles beleg- bzw. beweisbar..
So oder so - Die Absprache war hier schon lange und das illegale Handeln wird geduldet. da es von den Caymans gesteuert wird...
Ziel ist hier nicht Geld zur Finazierung der Firma zu bekommen, sondern die Anteile zu verteilen...

[Shanghai2006]

This is maybe a little bit old info, but might give you a detail info what happened and what might can happen. Still risky stock and all depends on the outcome of the Europe trials.

Cytori Therapeutics Inc (NASDAQ:CYTX) Could Still Win In Scleroderma. Here's How.

By Chris Sandburg
Posted on July 25, 2017

If you are looking for one of the biggest biotechnology losses of the week so far, look no further than Cytori Therapeutics Inc (NASDAQ:CYTX). The company closed out last week at around $1.10 a share. By market open on Monday, Cytori went for around $0.40 apiece and remained pretty much flat on the open to close out the session at $0.48 a share.

The decline comes on the back of the company putting out data from one of its lead investigations and – as readers might have guessed – the data not hitting press as Cytori or its shareholders might have hoped it would.

Markets are asking the question – is there any value in picking up exposure at current prices or is this an asset (and in turn, a company) to write off for now?

Here is our answer to that question.
The trial was rooted in a drug called Habeo that attempts to use what are called dipose-derived regenerative cells (ADRCs), which are living cells that are present in an adult human’s own adipose tissue, to help regenerate healthy tissue in conditions associated with cell degeneration. The company removes these cells from the patient using liposuction, adds them to a liquid suspension and then concentrates them into a substance that can be reintroduced into the body by way of subcutaneous injection.
In this instance, the target indication was scleroderma, which is a rare and chronic connective tissue disease generally classified as an autoimmune rheumatic disorder. It’s characterized by significant hand dysfunction, and this latter characterization played a key role in the trials determinant outcome.
So, specifically, the company injected its Habeo therapy into a total of 88 patients with scleroderma, including 51 patients with a type called diffuse cutaneous and 37 with another type called limited cutaneous scleroderma. These patients were then followed up at 24 and 48 weeks’ post-treatment to see if their scleroderma had improved, using a scale called the Cochin Hand Function Score (CHF score) to judge improvement.
As per the latest data, the drug failed against its primary endpoint (an improvement from baseline based on the above-mentioned CHF score) at both 24 weeks and 48 weeks.

So, not great.

It’s not all bad, however. The company did manage to show some degree of improvement (a statistically significant one at that) in one of the subgroups of patients – the patients with the diffuse cutaneous form of the disease.

This part is important: if this improvement was recognized after the trial as part of a post completion analysis, we would write it off entirely. However, this was a prespecified subgroup and – while the drug didn’t work across the entire population – the company was able to show that it might work in a certain group of patients and, for us, that’s enough to warrant some degree of optimism, especially at current bargain bin prices.
Of course, if the company is going to recover any of the lost strength, it’s going to need a catalyst, so where is that coming from?
Well, this trial was in the US but there is also a very similar trial currently underway in Europe. The trial in question, called SCLERADEC-II, is a 40 patient study looking at the same patient population. if the data shows that the drug works in the diffuse subset of the population in this trial, or in other words, if it supports the efficacy readout in this population that we just got from the US study, there’s a good chance we will see this company start to pick up some of its lost strength.
Sure, markets are disappointed with Cytori’s seeming failure to target the entire scleroderma population, but if it can target a subsection, then there is still a fair amount of value in its primary asset. An estimated 300,000 Americans have scleroderma, about one-third of whom have the systemic form of the disease, known as systemic sclerosis (SSc). SSc is further broken into the two above noted categories – diffuse cutaneous and limited cutaneous SSc. Diffuse scleroderma (what we’re interested in here) accounts for between one-third and one-half of all cases of systemic sclerosis. Using these numbers, there are around 30,000-50,000 US patients that this drug seems to work for and approximately twice that in Europe.

To answer the question, then, yes, there’s still plenty to be optimistic about for Cytori and we’re looking to the outcome of SCLERADEC-II as a potential gap-closing catalyst as and when it hits press.

https://insiderfinancial.com/heres-why-you-shouldnt-write-of…

[Shanghai2006]

Cytori Therapeutics (CYTX) Says Its STAR Trial Data Accepted for Presentation at Systemic Sclerosis World Congress

November 7, 2017 9:11 AM EST

Cytori Therapeutics, Inc. (Nasdaq: CYTX) announced today that its U.S. STAR clinical trial assessing the safety and efficacy of Habeo™ Cell Therapy for hand dysfunction due to systemic scleroderma (SSc) has been accepted for presentation at the 5th Systemic Sclerosis World Congress on February 15-17, 2018 in Bordeaux, France.

The presentation will include a full data analysis, beyond the top-line results previously reported by the company in July and October 2017, specifically:
While there were trends toward greater improvement in the primary endpoint, Cochin Hand Function Score [CHFS], for Habeo compared to placebo at 24 and 48 weeks, for both time points these differences did not achieve statistical significance of p≤0.05.
The pre-specified analysis of 51 subjects with diffuse SSc showed a clinically meaningful treatment benefit at 48 weeks in both the CHFS (improvement of 12.0 points for Habeo compared to 6.6 in the placebo group) and in a secondary endpoint, the Health Assessment Questionnaire Disability Index [HAQ-DI] (improvement of 0.21 points compared with 0.04 in the placebo). These differences approached or achieved statistical significance (p=0.069 and p=0.044, respectively).

Subsequent data analysis of these and other key endpoints in patients with diffuse SSc are also consistent with a treatment effect:
Responder analysis for the HAQ-DI score at 48 weeks, based on published minimal clinical important differences, showed that 63% of patients in the Habeo group had a clinically-important improvement compared with only 26% of patients in the placebo group (p=0.019)
A standardized measure of health-related quality of life, EQ-5D, showed that 50% of patients in the placebo group exhibited clinically-important worsening at 48 weeks compared to only 3% in the Habeo group (p=0.0002).
Patients in the Habeo group, compared to the placebo group, also exhibited a reduced number of new ulcers over the 48 week study period (mean 1.72/patient compared with 3.74/patient in the placebo group; p=0.178), delayed time to first new ulcer (p=0.116), and greater improvement in hand mobility at 48 weeks, as measured by 2nd-4th corner distance of right hand (~5.5 mm increase vs. ~0.6 mm decrease, respectively; p=0.135).

The full data set will be presented at the 5th Systemic Sclerosis World Congress on February 15-17, 2018.

STAR was a randomized, placebo-controlled, double-blind, parallel group, U.S. clinical trial intended to study the safety and efficacy of Habeo Cell Therapy in 88 subjects with hand dysfunction due to scleroderma at 19 U.S. centers. Cytori is currently working with statisticians and study investigators in preparation for publication of these results in a peer-reviewed journal.

https://www.streetinsider.com/Corporate+News/Cytori+Therapeu…

[Shanghai2006]

Cytori's generic doxorubicin candidate ATI-0918 matches branded versions in bioequivalence study; shares ahead 4%

Nov. 16, 2017 11:53 AM ET|About: Cytori Therapeutics Inc (CYTX)|By: Douglas W. House, SA News Editor

•Cytori Therapeutics (CYTX +4.3%) is up, albeit of light volume, in response to the results from a pharmacokinetic bioequivalence study comparing its doxorubicin hydrochloride candidate ATI-0918 to Johnson & Johnson (JNJ -0.1%) unit Janssen's CAELYX and Sun Pharma's Lipodox. The data were presented at the American Association of Pharmaceutical Scientists Annual Meeting in San Diego.

•The study confirmed bioequivalence.

•Cytori is actively seeking commercial partners for the asset.

https://seekingalpha.com/news/3312933-cytoris-generic-doxoru…

[Shanghai2006]

Cytori Reports Reduction in Fibrosis Parameters in Scar Study

GlobeNewswire•November 20, 2017

SAN DIEGO, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (CYTX) announced today the publication of preclinical data from a study using Cytori Cell Therapy™ in a model of fibrotic scar formation. This study was performed with support from the Biomedical Advanced Research and Development Authority (BARDA) as a component of the preclinical proof of concept data package incorporated into the FDA approved United States RELIEF Trial.

The publication describes a study in which Adipose Derived Regenerative Cells (ADRCs), the active component of Cytori Cell Therapy™, were injected into deep partial thickness wounds in a porcine model, considered the gold standard preclinical model of hypertrophic scarring. Six months after treatment, wounds that were treated with ADRCs showed reduction in parameters associated with hypertrophic scarring compared to control wounds. Parameters that were improved by treatment included skin hardness, organization, vascularity, and discoloration. Molecular analysis implicated the temporal modulation of Interleukin-6 expression, a key regulator of the inflammatory response, as a potential mediator of the effect.

The paper entitled “Autologous adipose-derived regenerative cell therapy modulates development of hypertrophic scarring in a red Duroc porcine model ” just published in the journal Stem Cell Research and Therapy and is now available online.

The findings from this preclinical study were incorporated into the design of the RELIEF clinical trial of Cytori Cell Therapy™ which is also funded by BARDA. The RELIEF trial will assess Cytori Cell Therapy in human patients with substantial thermal burn injury. In addition to assessment of early healing, the RELIEF trial will evaluate several scar-related parameters using approaches similar to those applied in this study.

“Fibrosis is a common factor in both burns and scleroderma.” said Dr. John Fraser, Chief Scientist at Cytori. “This preclinical study is consistent with a number of emerging studies indicating a beneficial effect of Cytori’s ADRC technology in fibrotic disease.”

The treatment of thermal burns remains a critical unmet medical need. Despite standard of care primarily consisting of dressings, skin grafts and skin substitutes, patients frequently suffer from pain, scarring, skin contracture and reduced range of motion. Hypertrophic scarring is characterized by raised, discolored, itchy and painful scars that are a common fibrotic consequence of deep-partial thickness burn injury.

Autologous cell therapies such as those offered by Cytori have the potential to improve the quality and rate of wound healing and reduce scarring. In a mass casualty event, the Government Accountability Office estimates that as many as 10,000 patients could require thermal burn care. The limited number of specialist surgeons and burn centers in the U.S. creates a public health need for a burn wound therapy that can be quickly and broadly applied by non-specialist medical personnel following such an event. Therefore, autologous Cytori’s Cell Therapy represents a novel medical countermeasure not only to address these challenges but also to promote wound healing and tissue repair and improve casualty care.

About RELIEF
The RELIEF trial will assess safety and feasibility of intravenous delivery of Cytori Cell Therapy™ as an adjunct to usual care in patients with thermal burn injuries covering between 20% and 50% of their body surface area. Subjects will have at least one deep partial or full thickness burn wound that is to be treated with a meshed autologous split thickness skin graft (STSG). Subjects will be randomized (1:2) to receive either usual care alone or usual care supplemented with Cytori Cell Therapy. While primarily focusing on safety and feasibility, the RELIEF trial will also assess a series of parameters related to skin graft healing. The trial is approved to enroll up to 30 patients in up to 10 U.S. sites with study initiation expected to occur soon.

https://finance.yahoo.com/news/cytori-reports-reduction-fibr…

[Shanghai2006]

Here’s Why Cytori Therapeutics Inc (CYTX) Shares Skyrocketed Today

Corey Williams-January 5, 2018, 5:20 PM EDT

Cytori Therapeutics Inc (NASDAQ:CYTX) was Wall Street’s bull of the day today with shares that flew 74%.

The cause of all the enthusiastic commotion? Japanese drug giant Takeda Pharmaceutical intends to acquire TiGenix, an advanced biopharmaceutical company developing novel stem cell therapies for serious medical conditions, at an acquisition price of EUR 1.78 per share, representing a transaction value of approximately EUR 520 million on a fully diluted basis. Investors see the acquisition of Tigenix as a positive “interest” signal for the regenerative medicine space and specifically for Cytori which has a similar adipose based product.

On the ratings front, Cytori has been the subject of a number of recent research reports. In a report released today, Maxim analyst Jason Kolbert assigned a Buy rating on CYTX, with a price target of $5.00, which represents a potential upside of 1752% from where the stock is currently trading. On November 10, B.Riley FBR’s Andrew D’silva maintained a Hold rating on the stock and has a price target of $0.50.

https://www.smarteranalyst.com/2018/01/05/heres-cytori-thera…

[Shanghai2006]

Cytori Therapeutics jumps as Maxim sees it as takeover candidate

Jan. 5, 2018 6:42 PM ET|About: Cytori Therapeutics Inc (CYTX)|By: Jason Aycock, SA News Editor

•Nanocap Cytori Therapeutics (NASDAQ:CYTX) vaulted in the last 15 minutes of the week's trading to a 74% gain after it was floated as a likely acquisition candidate by Maxim.

•Analyst Jason Kolbert sees Takeda's (OTCPK:TKPYY) play for Tigenix (NASDAQ:TIG) as a positive sign for Cytori, since it makes a similar adipose-based product for regenerative medicine.

•He has a price target of $5 vs. today's close of $0.47.

•Volume was about 7.7M shares today vs. an average of less than 1M. Shares have drawn back slightly postmarket, -13%.

•Source: Bloomberg

https://seekingalpha.com/news/3321520-cytori-therapeutics-ju…

[Hubertuss]

Von Ariva.de, user warkla2 geliehen:

Corey Williams - 5. Januar 2018, 17:20 Uhr EDT Teilen auf:
Cytori Therapeutics Inc (NASDAQ: CYTX ) war heute der Bullenmarkt der Wall Street mit Aktien, die 74% flogen.

Die Ursache all der begeisterten Aufregung? Der japanische Pharmariese Takeda Pharmaceutical beabsichtigt, TiGenix, ein fortschrittliches biopharmazeutisches Unternehmen, das neue Stammzelltherapien für ernsthafte Erkrankungen entwickelt, zu einem Kaufpreis von 1,78 Euro pro Aktie zu erwerben. Dies entspricht einem Transaktionswert von rund 520 Millionen Euro auf vollständig verwässerter Basis. Investoren sehen in der Akquisition von Tigenix ein positives "Interesse" -Signal für den Bereich der regenerativen Medizin und speziell für Cytori, das ein ähnliches Produkt auf Fettbasis hat.



Gruß

[Shanghai2006]

War ja richtig anstrengend heir, kaufen, verkaufen, die 2 Spruenge gut mitgemacht im Januar.

Hoffe das es wieder runtergeht, damit ich nochmals einkaufen kann. Hab alles raus letzte Woche.

Cytori ist for mich ein richtiger Shortstock.

[Shanghai2006]

Cytori readies subscription rights offering
Apr. 28, 2018 11:50 AM ET|About: Cytori Therapeutics Inc (CYTX)|By: Douglas W. House, SA News Editor
Cytori Therapeutics (NASDAQ:CYTX) has filed a prospectus for a subscription rights offering to existing shareholders.
The free-of-charge non-transferable offering will provide for the purchase one Unit for each share owned. Each unit will consist of one share of common stock and one warrant to purchase one share of common. Price, volume and terms have yet to be announced.

https://seekingalpha.com/news/3350070-cytori-readies-subscri…

https://seekingalpha.com/filing/3993332?uprof=45

[Shanghai2006]

Cytori Provides Update on US Manufacturing and EU Approval Plans for ATI-0918, Liposomal Doxorubicin
Apr 30, 2018

SAN DIEGO, April 30, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (Nasdaq:CYTX) (“Cytori” or “the Company”) today provided an update on its plans for US manufacturing and EU approval for its ATI-0918 liposomal doxorubicin product. ATI-0918 has been designed and developed to be bioequivalent to the market leading branded reference drug, Caelyx/Doxil (Johnson & Johnson).

Liposomal doxorubicin is a commonly used cytotoxic agent for recurrent breast and ovarian cancer, multiple myeloma and Kaposi’s sarcoma. The global market is anticipated to grow to $1.4B by 2024 (Grand View Research, Inc., 28 2nd Street, Suite 3036, San Francisco, CA, 94105, United States).

Cytori intends to first seek European approval for its drug and has applied for and has received EMA approval to file for centralized European Union (EU) approval. Generic medicines in Europe can be approved either centrally via the European Medicines Agency (EMA) or nationally via the local regulatory body. Approval by EMA using a centralized procedure leads to approval of the product in all 28 EU Member States, Iceland, Liechtenstein and Norway.

All states of manufacturing of the product will be performed in the United States. More specifically, manufacturing of the cytotoxic liposomal formulation will be performed in Cytori’s San Antonio Texas facility. Cytori’s facility features a new manufacturing clean room and technology specifically designed for the manufacture of complex liposomal compounds integrating cytotoxic compounds. In addition, Cytori has in house analytical chemistry capabilities to ensure its products are manufactured to the highest quality standards.

Final sterile packaging and fill finish activities will also be performed in the United States by Bryllan, located in Brighton, Michigan. Bryllan is a premier commercial scale contract manufacturing organization capable of safely filling potent and cytotoxic compounds, hormones, antibodies and complex biologics, live viruses and vaccines. Bryllan features a state-of-the-art aseptic production facility using isolators as the core technology with the highest engineering standards of design and construction to meet US FDA and other global regulatory standards.

http://ir.cytori.com/investor-relations/news/news-details/20…

[Baroh]

Gute Aussichten für die Zukunft!?

http://www.4-traders.com/CYTORI-THERAPEUTICS-INC-27535809/ne…

[Shanghai2006]

Cytori Therapeutics Inc (NASDAQ:CYTX): Are Analysts Optimistic?

Dane Simmons
Simply Wall St.May 26, 2018

Cytori Therapeutics Inc’s (NASDAQ:CYTX): Cytori Therapeutics, Inc., a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. The US$16.16M market-cap company’s loss lessens since it announced a -US$26.66M bottom-line in the full financial year, compared to the latest trailing-twelve-month loss of -US$23.53M, as it approaches breakeven. As path to profitability is the topic on CYTX’s investors mind, I’ve decided to gauge market sentiment. In this article, I will touch on the expectations for CYTX’s growth and when analysts expect the company to become profitable.

CYTX is bordering on breakeven, according to analysts. They expect the company to post a final loss in 2019, before turning a profit of US$25.48M in 2020. CYTX is therefore projected to breakeven around 2 years from now. In order to meet this breakeven date, I calculated the rate at which CYTX must grow year-on-year. It turns out an average annual growth rate of 72.13% is expected, which is extremely buoyant. If this rate turns out to be too aggressive, CYTX may become profitable much later than analysts predict.

I’m not going to go through company-specific developments for CYTX given that this is a high-level summary, though, bear in mind that typically a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.

Before I wrap up, there’s one issue worth mentioning. CYTX currently has a debt-to-equity ratio of 161.90%. Generally, the rule of thumb is debt shouldn’t exceed 40% of your equity, and CYTX has considerably exceeded this. Note that a higher debt obligation increases the risk around investing in the loss-making company.

Next Steps:
There are too many aspects of CYTX to cover in one brief article, but the key fundamentals for the company can all be found in one place – CYTX’s company page on Simply Wall St. I’ve also put together a list of important aspects you should further examine:
Valuation: What is CYTX worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether CYTX is currently mispriced by the market.

Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Cytori Therapeutics’s board and the CEO’s back ground.
Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

https://finance.yahoo.com/news/cytori-therapeutics-inc-nasda…

[Shanghai2006]

Cytori details subscription rights offering

Jun. 12, 2018 9:31 AM ET|About: Cytori Therapeutics Inc (CYTX)|By: Douglas W. House, SA News Editor

Cytori Therapeutics (CYTX) advises investors to buy shares by Friday, June 22, in order to quality for its planned rights offering.
Shareholders of record on that date will receive one non-transferable subscription right for each common share or Series B Convertible Preferred share held.

Each right will entitle the holder to purchase one unit at $1,000 per unit, each consisting of one share of Series C Convertible Preferred Stock and 200 warrants to purchase Cytori common stock at $3.17 per share. Each Series C share, with a face value of $1,000, will be immediately convertible into common shares at $2.64.

The rights may be exercised until 5:00 pm ET on Friday, July 13, unless extended by the company.

https://seekingalpha.com/news/3363289-cytori-details-subscri…

[Shanghai2006]

Cytori Reports Improved Skin Healing in Pivotal Burn Preclinical Study
Jun 28, 2018

BARDA Funded Study Published in the Journal “Burns”
SAN DIEGO, June 28, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (Nasdaq:CYTX) announced today the publication of preclinical data from a study using intravenous delivery of Cytori Cell Therapy™ in a model of large burn injury representative of patients being recruited in the ongoing RELIEF clinical trial. This study was performed with support from the Biomedical Advanced Research and Development Authority (BARDA) as a component of the preclinical data supporting the FDA approved United States RELIEF Trial.

In the study described in this publication, Adipose Derived Regenerative Cells (ADRCs), the active component of Cytori Cell Therapy™, were delivered by intravenous injection in a porcine model of mixed full-and partial thickness burn injury covering approximately 20% of total body surface area in which full thickness burns were treated with a meshed autologous split-thickness skin graft. All animals received skin grafting procedures, burn dressings, and other supportive care commonly used in burn centers around the USA.

No serious adverse events related to ADRC infusion were noted in any of the animals. Delivery of ADRCs appeared to be safe with none of the systemic safety parameters worsened compared to the control group. Importantly, skin graft healing was significantly faster in ADRC-treated animals such that five days after treatment wounds in animals treated with ADRCs were 27.1±11.8% epithelialized compared to only 1.1±1.1% in control animals (p<0.05). Skin barrier function (ability to prevent water loss) was 20-fold greater in ADRC-treated wounds than in controls on Day 9 after treatment (32.8±6.3 vs. 157.8±57.3 g/m2/h, respectively; p=0.01). Skin biological elasticity was also significantly greater in ADRCs-treated animals compared to those treated with LR (0.50±0.1 vs. 0.44± 0.02, respectively; p=0.017). Similar improvement in healing was also evident in donor sites (epithelialization 52.8% vs. 33.1% on Day 5 post-treatment) and partial thickness burn (epithelialization 81.8% vs. 59.8% on Day 18 post-treatment).

Overall, the results of this study showed that healing of skin grafts occurred more rapidly in ADRC-treated animals than in controls with more rapid formation of new skin (epithelialization), earlier restoration of skin function (ability to resist water evaporation), and improved skin elasticity.
The paper entitled “Preclinical Assessment of Safety and Efficacy of Intravenous Delivery of Autologous Adipose-Derived Regenerative Cells (ADRCs) in the Treatment of Severe Thermal Burns using a Porcine Model” was published today in the journal Burns and is now available online.
The findings from this preclinical study have been incorporated into the design of the RELIEF clinical trial of Cytori Cell Therapy™ which is also funded by BARDA. The RELIEF trial is designed to assess Cytori Cell Therapy in human patients with substantial thermal burn injury using several of the end points used in this preclinical study including epithelialization, skin barrier function, and skin elasticity.

“Healing of meshed skin grafts remains an important clinical problem in burn care,” said Dr. John Fraser, Chief Scientist at Cytori. “We look forward to adding to the number of clinical sites already recruiting patients for the RELIEF trial and to assessing clinical data from RELIEF which applies the same treatment approach to treat very similar wounds.”

The treatment of thermal burns remains a critical unmet medical need. Despite standard of care primarily consisting of dressings, skin grafts and skin substitutes, patients frequently suffer from slow healing, pain, scarring, skin contracture and reduced range of motion.
Autologous cell therapies such as those offered by Cytori have the potential to improve the quality and rate of wound healing and reduce scarring. In a mass casualty event, the U.S. Government Accountability Office estimates that as many as 10,000 patients could require thermal burn care. The limited number of specialist surgeons and burn centers in the U.S. creates a public health need for a burn wound therapy that can be quickly and broadly applied by non-specialist medical personnel following such an event. Therefore, autologous Cytori’s Cell Therapy represents a novel medical countermeasure not only to address these challenges but also to promote wound healing and tissue repair and improve casualty care.

About RELIEF
The RELIEF trial is designed to assess safety and feasibility of intravenous delivery of Cytori Cell Therapy™ as an adjunct to usual care in patients with thermal burn injuries covering between 20% and 50% of their body surface area. Subjects will have at least one deep partial or full thickness burn wound that is to be treated with a meshed autologous split thickness skin graft. Subjects will be randomized (1:2) to receive either usual care alone or usual care supplemented with Cytori Cell Therapy. While primarily focusing on safety and feasibility, the RELIEF trial is also designed to assess a series of parameters related to skin graft healing. The trial is approved to enroll up to 15 patients in up to 10 U.S. sites. The trial has been initiated at two sites. Cytori anticipates adding additional sites at a cadence of approximately one per month.

http://ir.cytori.com/investor-relations/news/news-details/20…

[Hubertuss]

Antwort auf Beitrag Nr.: 55.427.826 von Merton75 am 31.07.17 17:07:54

Merton75 ist das auf deinem Mist gewachsen?

Gruß



SHAREHOLDER ALERT Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Cytori Therapeutics, Inc.

Nachrichtenquelle: Business Wire (engl.) | 18.05.2018, 23:33 | 1453 | 0 | 0 Levi & Korsinsky announces it has commenced an investigation of Cytori Therapeutics, Inc. (NASDAQCM: CYTX) concerning possible breaches of fiduciary duty.

To obtain additional information, go to: http://www.zlkdocs.com/CYTX-Info-Request-Form-6739 Anzeige powered by finative or contact Joseph E. Levi, Esq. either via email at [e-mail] or by telephone at [phone], toll-free: [phone]. There is no cost or obligation to you. Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes. View source version on businesswire.com: https://www.businesswire.com/news/home/20180518005784/en/

Zitat von Merton75: Sollte sich ja rausfinden lassen wem die Seit(en) gehören und wer gepusht hat.
Zudem ist die Akquisition in 2017 in Kombination zu einer KE zu 1$ (bei einem Kurs von 2$) mehr als "dubios" bei gleichzeitigen Schulden inkl. einer Marketcap. von nun 15m$.. Bei einem Chapter 11 wird man sehen an wen das alles geht und ob der "Investor" an allem beteiligt war. (gibt jeden Jahr zig Bspw. und über Konten ließe sich das nachweisen, wenn man wollen würde)
Alles in allem ein Beweis das dies mehr ist als Roulette, da es hierbei wenigstens eine Überwachung gibt und man von einem legalen Spiel ausgehen kann...

[Hubertuss]

Bitte um Hilfestellung zur jüngsten KE:

Cytori Therapeuties Inc.
Registered Shares DL - ,001

Sie erhalten Rechte (XC000A2JNRP2) im Verhältnis 1:1 eingebucht.

Für jeweils ein Bezugsrecht kann eine Unit, bestehend aus einer Vorzugsaktie Ser. C und 200 Optionsscheine (ISIN unbekannt), zum Preis von USD 1.000,00 je Unit bezogen werden.

Der Optionsschein kann innerhalb von 30 Monaten nach Ausgabe, im Verhältnis 1:1 und unter Zuzahlung von USD 3,17 in Aktien der Gesellschaft ausgeübt werden.


Danke
Gruß

[Merton75]

Antwort auf Beitrag Nr.: 58.305.095 von Hubertuss am 26.07.18 08:57:28

Leider nicht wobei ich der SEC diese Vorfälle seit ca. 8 Jahren konsequent melde aber das hier betrifft "nur die Anzahl Aktien", d.h. die Flutung durch das "Management" mit den "dubiosen KE´s" und dem Dealer Maxim Group LLC.
Ich denke das nun auch der letzte gesehen hat was hier abgeht!
6.2m Aktien mit einem Split von 1:10 sind 62m Aktien.. Wiederum mit einem Split von 1:15 - Also 930!! MILLIONEN Aktien - Im Vergleich zum Start von 4! Millionen Aktien (Unabhängig der B und C Aktien sowie Optionen!)

Die Jungs untersuchen nun wie es dazu kommen konnte das soviele Aktien von "den Aktionären" auf der "HV" durchgewunken wurden.
Man siehe nur "die letzte KE" mit einer VERDOPPELUNG der Anzahl Aktien.

Des Weiteren sind die Postbank und weitere Finanzdienstleiter dabei (letztes Jahr bei 0.7 bzw heutigen 7$).. Es ist so ersichtlich was die Jungs hier machen das es noch günstiger wird als Chapter 11. Das hier ist so ein Abzug unter Aufsicht der SEC das man sich fragen muss ob es überhaupt eine Börsenaufsicht gibt. Selbst die "Aquisition" von Azaya ist nun mehr wert als die ges. Marketcap. von der Bude hier..

Wie gesagt.. Das hier ist einer der größten Manipulationen die ich je gesehen habe und da ich seit 8 Jahren schreibe und auf der SEC melde frage ich mich wirklich ob es eine Aufsicht gibt oder nicht..

Einfacher kann man sein Geld nicht verdienen... (und alle verdienen mit inkl. "dem Managemen" wie man jüngst wieder sehen konnte - "Optionen" und die Gehälter sind ein vielfaches der Marketcap!)
Das Konglomerat aus "Hedgefonds und Finanz.." sowie dem Management und Dealer Maxim ist aber bisher nicht aufgeflogen. Hoffen wir mal das sich das ändert aber so wie uns die Vergangenheit lehrt....

[Merton75]

Antwort auf Beitrag Nr.: 55.537.173 von Merton75 am 16.08.17 16:48:17

Zitat von Merton75: Das ist keine "normale KE", sondern eine Absprache zwischen "dem Unternehmen", den Hedgefonds und "weiteren Insidern" inkl. der SEC (Daher auch keine "Daten gefüllt" im SEC Filling)
Hier wird die komplette Marktkap. innerhalb eines Jahres mit Warrents verdoppelt (wie auch vorher wobei die Geschwidigkeit unfassbar ist).
Es gibt zwei Strategien - entweder die Jungs machen so weiter bis einer alle Aktien hat oder es wird so vor die Wand gefahren und einer übernimmt die Anteile.. Vorher wird mit Shorts Geld gemacht und Aktien gezielt verkauft
(Es ist auch kein Zufall das 11 Mill. Aktien nach einem Absturz von 60% kommen. Vorher hatte man auch bei 2$ absichtlich eine Meldung rausgebracht um eine KE zu 1$ durchführen zu können - am selben Tag ) - alles beleg- bzw. beweisbar..
So oder so - Die Absprache war hier schon lange und das illegale Handeln wird geduldet. da es von den Caymans gesteuert wird...
Ziel ist hier nicht Geld zur Finazierung der Firma zu bekommen, sondern die Anteile zu verteilen...

[Merton75]

Antwort auf Beitrag Nr.: 58.321.136 von Hubertuss am 27.07.18 19:46:32

25.06.2018 - 3.17$ (Subscription Rights to Purchase Up to 25,000 Units Consisting of an Aggregate of Up to 25,000 Shares of Series C Preferred Stock and Warrants to Purchase Up to 5,000,000 Shares of Common Stock)

Each subscription right will entitle you to purchase one Unit, which we refer to as the Basic Subscription Right, at a subscription price per Unit of $1,000, which we refer to as the Subscription Price. Each Warrant entitles the holder to purchase one share of common stock at an exercise price of $3.17 per share from the date of issuance through its expiration 30 months from the date of issuance.

09.07.2018 - 1.27$ (Subscription Rights to Purchase Up to 20,000 Units Consisting of an Aggregate of Up to 20,000 Shares of Series C Preferred Stock and Warrants to Purchase Up to 12,420,000 Shares of Common Stock)

Each subscription right will entitle you to purchase one Unit, which we refer to as the Basic Subscription Right, at a subscription price per Unit of $1,000, which we refer to as the Subscription Price. Each Warrant entitles the holder to purchase one share of common stock at an exercise price of the lesser of (a) $1.27 per share and (b) the conversion price per share of the Series C Preferred Stock, from the date of issuance through its expiration 30 months from the date of issuance. If you exercise your Basic Subscription Rights in full, and any portion of the Units remain available under the Rights Offering, you will be entitled to an over-subscription privilege to purchase a portion of the unsubscribed Units at the Subscription Price, subject to proration and ownership limitations, which we refer to as the Over-Subscription Privilege. Each subscription right consists of a Basic Subscription Right and an Over-Subscription Privilege, which we refer to as the Subscription Right.

17.07.2018 - 0.9$
Warrants Erhöhung auf 21,000,000 Shares

Zwischen diesen Daten wurde von ca. 2$ auf 0,64 gedrückt weil Maxim ja noch 6 Mill. Aktien bekommen hat zur Verlosung (unter Beachtung einer 10D Avg Vol 260T).. 2/0,64 = 3,125 = 210% Kursanstieg notwendig innerhalb von einem Monat...)

Man sieht es jedes Mal seit 8 Jahren.. Jetzt gibts sogar B und C Aktien soviel gefluttete Warrents und Optionen für das "Management"..

Maxim hat bestimmt schon 100 Millionen hier verdient und auch die Hedgefonds die rauf und runter ziehen.. (Beachtung von Volumen!!)

[Merton75]

Weiteres Bsp. (NUR DREI PERSONEN)

Marc H. Hedrick, M.D., 752,523 + Bonus von 109,688
Tiago M. Girão, 410,095 + 59,670
John D. Harris, 616,979 + 48,274

Dazu bekommen die jungs noch Tausende optionen seit Jahren die sie wieder auf den Markt hauen und dadurch sicherlich auch noch jeder über 100T Euro machen (keiner KAUFT hier Aktien mit dem eigenen Geld!!)

Operating expenses: General and administrative 7,594; Research and development 11,678; Sales and marketing 3,593; Principal payments on long-term obligations 4,720

Bei der jetzigen Marketcap. kann sich jeder ausmalen was passieren wird

[Merton75]

Antwort auf Beitrag Nr.: 58.333.821 von Merton75 am 30.07.18 15:20:34

Es gibt verschiedene Tatsachen seit über acht Jahren

- Tiago hat es geschafft von über 400$ auf 0,4 zu drücken. In der Zeit hat er die Aktienanzahl um 200 Millionen erhöht. Als Belohung gab es fast eine Verdoppelung des Gehalts.
- Die Wirtschaftsprüfer von der Company von der er gekommen ist spielen mit (sieht man am Gehalt der drei Personen und der "peer Group")
- Sabby Mgmt und Co wie Postbank haben hier mit riesen Volumina gedrückt und Geld gemacht
- Bei einem Chapter 11 wäre der Kaufpreis um 100 Millionen teurerer und man sieht was gemacht witd
- DREI PERSONEN bekommen nun mehr GEHALT als die ges. Marktkap. der Firma
- Die Auswertung von Konten der bet. Firmen und Personen sowie die "Stimmenauswertung auf der HV" wird selbst durch eine Anwaltskanz. nicht aufgedeckt
- selbst Martin Shkreli letzte Betrugsgeschichten waren nicht so krass und wurde "bestraft" obwohl es bei weitem nicht so war wie hier
- "Der Dicke" der nun diese Comp. kaufen wird für unter 1Cent (im Übertragenden Sinne ist der Kurs hier bei 0,0024 CENT!!!!) (akt. Kurs (10 (Split 1) / 15 (Split2) )oder einer seiner Vertrauten
- usw.

Es ist dermaßen illegal und keine SEC oder Aufsichtsbehöre schaut hier zu, da auch hier Geld fließen wird.

[Shanghai2006]

Cytori Therapeutics Inc (CYTX) CEO Marc Hedrick on Q2 2018 Results - Earnings Call Transcript
Aug. 14, 2018 10:05 PM ET

https://seekingalpha.com/article/4199210-cytori-therapeutics…

[Shanghai2006]

Cytori Therapeutics Inc (CYTX)
FORM 10-Q | Quarterly Report
Aug. 14, 2018 4:31 PM

https://seekingalpha.com/filing/4138008

[Shanghai2006]

Cytori Therapeutics Inc (CYTX)
FORM 8-K | Current report
Aug. 14, 2018 4:25 PM

https://seekingalpha.com/filing/4137990

[Shanghai2006]

Cytori Reports Publication of Interim Pilot Data for Cell Therapy in Vocal Fold Scarring
Aug 09, 2018

SAN DIEGO, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced publication in the peer-reviewed journal, Stem Cell Research and Therapy, of “Autologous adipose-derived stromal vascular fraction and scarred vocal folds: first clinical case report.” This report describes preliminary data from the CELLCORDES trial of Cytori Cell Therapy™ (ADRCs) in patients with severe voice dysfunction due to scarring of the vocal fold (vocal cords).
The CELLCORDES trial is a fully-enrolled investigator-initiated pilot trial conducted using Cytori Cell Therapy. The trial is being performed by Investigators at the Department of Oto-Rhino-Laryngology and Head and Neck Surgery of Aix-Marseille University and the Cell Therapy Laboratory of La Conception University Hospital, both of Marseille, France. Additional details on the trial may be found at clinicaltrials.gov.

The reported index patient had severe vocal dysfunction persisting for four years following traditional surgery to treat chronic vocal fold lesions. Twelve months after single direct administration with 12 million ADRCs, the patient exhibited improvements in Vocal Handicap Index and other qualitative and quantitative measures of voice quality including: Hirano’s GRB scale (measuring vocal hoarseness, roughness, and breathiness), Jitter (a measure of uncontrolled variation in frequency of the voice), and vocal range. The authors noted that while the remaining seven patients treated in the CELLCORDES study have yet to complete 12-months of follow-up, no serious adverse events have been reported in any subject and no subject has reported worsening of vocal function. Furthermore, three are exhibiting “very good results (especially on the VHI)”.

http://ir.cytori.com/investor-relations/news/news-details/20…

[Shanghai2006]

Cytori Therapeutics, Inc. shares closed up about 46% on nearly 4.3 million shares traded yesterday on no particular news. It was about a week ago that the San Diego-based pharmaceutical company had reported second quarter earnings. For the quarter, Cytori reported a loss of 59 cents per share. This missed analysts' expectations of loss per share of 50 cents. Revenue was $1.6 million. CEO Marc Hedrick said during the earnings call, "Our goal is to be either the first or second generic on the market in Europe. The company also continues to engage and evaluate potential commercial partners for ATI-0918 in Europe, the Middle East, North Africa, North America and Asia Pacific regions. As mentioned before, the global market for this drug is estimated to be approximately $400 million to $750 million annually and in Europe, we estimated an annual market opportunity at approximately $120 million to $300 million." ATI-0918 is the company's lead drug candidate, a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types.

https://finance.yahoo.com/news/today-research-reports-stocks…

[Shanghai2006]

A good link for all biotech invested:

https://clinicaltrials.gov/ct2/results

You can save your search, by clicking/marking the save box.

Nice info about recruiting status.

[Shanghai2006]

Cytori Therapeutics Announces Receipt of Puregraft® Royalty Milestone

Oct 30, 2018

SAN DIEGO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (Nasdaq: CYTX) announced today it has received a milestone payment of $1.0 million from Bimini Technologies, LLC (Bimini). The payment is a result of Bimini achieving the first $10.0 million in gross profits for previous divestiture of the Puregraft® product line.

In 2013, Cytori entered into a Sale and Exclusive License/Supply Agreement with Bimini, pursuant to which Cytori sold to Bimini selected assets relating to Cytori’s Puregraft® product line, a series of standalone fat transplantation products that were developed to improve the predictability of outcomes for autologous fat grafting and aesthetic body contouring.

Bimini may also be obligated to make certain additional milestone payments to Cytori (in an aggregate amount of up to $10.0 million), contingent upon future achievement of certain milestones relating to Bimini’s gross profits from sales of the Puregraft products. The aggregate value of the consideration paid by Bimini to Cytori at the execution of the agreement in July 2013 was $5.0 million.

http://ir.cytori.com/investor-relations/news/news-details/20…

[Shanghai2006]

Cytori to become Plus Therapeutics
Jul. 16, 2019 4:42 PM ET|About: Cytori Therapeutics, Inc. (CYTX)|By: Douglas W. House, SA News Editor

Citing the need for a new identity to coincide with its new direction, Cytori Therapeutics (NASDAQ:CYTX) will change its name to Plus Therapeutics (PSTV). The change will take effect in several weeks.

The company's initial development focus will be on DocePLUS (formerly ATI-1123), an injectable, albumin-stabilized pegylated liposomal formulation of the chemo agent docetaxel. In other words, the formulation is more stable and longer-acting.

https://seekingalpha.com/news/3478248-cytori-become-plus-the…

[Hubertuss]

Antwort auf Beitrag Nr.: 61.072.237 von Shanghai2006 am 21.07.19 02:59:47

Was für ein Trauerspiel. Jetzt wird auch noch der Name geändert um neue Opfer f. dieses Spiel anzulocken.


Gruß

Zitat von Shanghai2006: Cytori to become Plus Therapeutics
Jul. 16, 2019 4:42 PM ET|About: Cytori Therapeutics, Inc. (CYTX)|By: Douglas W. House, SA News Editor

Citing the need for a new identity to coincide with its new direction, Cytori Therapeutics (NASDAQ:CYTX) will change its name to Plus Therapeutics (PSTV). The change will take effect in several weeks.

The company's initial development focus will be on DocePLUS (formerly ATI-1123), an injectable, albumin-stabilized pegylated liposomal formulation of the chemo agent docetaxel. In other words, the formulation is more stable and longer-acting.

https://seekingalpha.com/news/3478248-cytori-become-plus-the…

[Hubertuss]

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year



On August 5, 2019, Plus Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, as amended (the “Amendment”), with the Secretary of State of the State of Delaware to effectuate a one-for-fifty (1:50) reverse stock split (the “Reverse Stock Split”) of its common stock, par value $0.001 per share (the “Common Stock”), without any change to its par value. The Amendment became effective on the filing date. The Reverse Stock Split will be effective for trading purposes as of the commencement of trading on the Nasdaq Capital Market on August 6, 2019. There was no change in the Company’s Nasdaq ticker symbol, “PSTV,” as a result of the Reverse Stock Split. In connection with the Reverse Stock Split, the CUSIP number for the Common Stock has been changed to 72941H400. Upon effectiveness, each 50 shares of issued and outstanding Common Stock were converted into one newly issued and outstanding share of Common Stock. The Company’s 5,000,000 shares of authorized Preferred Stock were not affected by the Reverse Stock Split.



No fractional shares were issued in connection with the Reverse Stock Split. Any fractional shares of Common Stock that would have otherwise resulted from the Reverse Stock Split were rounded up to the nearest whole share. Outstanding equity awards and the shares available for future grant under the Company’s Amended and Restated 2004 Equity Incentive Plan, 2011 Employee Stock Purchase Plan, 2014 Amended and Restated Equity Incentive Plan and 2015 New Employee Incentive Plan were proportionately reduced (rounded down to the nearest whole share), and the exercise prices of outstanding equity awards were proportionately increased (rounded up to the nearest whole cent) to give effect to the Reverse Stock Split.



A copy of the Amendment is attached to this current report on Form 8-K as Exhibit 3.1, and the above summary is qualified in its entirety by reference to the full text of the Amendment.



Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.

[freixenetter]

alter schwede …

[MAINFRAME]

Antwort auf Beitrag Nr.: 61.277.877 von freixenetter am 16.08.19 17:45:49

Die ganzen letzten Jahre war‘s leider ein Trauerspiel, bis zum Reverse-Split letztens.
Habe hier schon 2006 verkauft (und in Betongold angelegt).
Mit dem Laden hat es einige ganz böse erwischt, Unverbesserliche Fans😩😩😩
Haben Haus und Hof verloren! Die ganz verrückten hatten sogar eine Macropore-Fansite! Dann wurde umbenannt in Cytori Therapeutics, jetzt Plus T.

[MAINFRAME]

Und nicht zu vergessen: die Herren Vorstände haben sich IMMER gut bedient, mit Optionen, Bonusaktien undundund.

[freixenetter]

+ 300 % intraday..

[MAINFRAME]

Schau mal in ein paar Tagen wieder rein. Bisher wurde alles zum abverkauf genutzt.Wobei diesmal das Volumen schon extrem hoch ist , 20 Mio. Gehandelt!!

[freixenetter]

Antwort auf Beitrag Nr.: 61.279.383 von MAINFRAME am 16.08.19 22:13:49

du lass mal🤣 das ist selbst mir zu heavy, mich machen die Schwankungen in meinem Depot jetzt schon schwindelig,

[Bullethead]

Kann mir einer erklären warum die Aktie gestiegen ist? Namensänderung und Reverse Split im vergangenen Monat können wohl kaum der Grund hierfür gewesen sein. Die Pipeline und FDA Zugeständnisse auch nicht oder habe ich etwas übersehen? Viele Grüße und schönen Sonntag noch

[MAINFRAME]

Würde sagen, einfach gute Quartalszahlen.

[Hubertuss]

O.k., das hatten wir bei Cytori schon mal. Bin damals recht gut aus scheinbar aussichtlosen Kursen richtig gut rausgekommen (hab diesen Sprung am Freitag nicht mitbekommen, erst eben. Ich hab mich mal schnell schlau gemacht ob da nicht wieder eine KE, Split oder sonst eine gemeinheit gegeben hat, aber nein, nur Zahlen).

Die Tage werden es sicher noch Zeigen.

Gruß

[C_laus]

Antwort auf Beitrag Nr.: 61.294.270 von Hubertuss am 19.08.19 20:38:57

Habe eben eine Mail bekommen, wonach Barda wohl am 9.10. 4,6 Mio $ überwiesen hat.
Habe eben noch mal nachgekauft. Der Kurs ist dermassen niedergeprügelt...
Außerdem gab es jüngst die KE zu 5 $

[Hubertuss]

Antwort auf Beitrag Nr.: 61.694.398 von C_laus am 15.10.19 12:59:31

Danke f. d. Info. Ich hab noch nix bekommen. Der bisherige Verlauf seit August gleicht leider dem bisherigen unter Cytori, schade.

Die 16$ wollte ich ja nicht so recht wahr haben und habe per heute uach recht bekommen.

Ich harre weiter!

Gruß

[C_laus]

Antwort auf Beitrag Nr.: 61.695.793 von Hubertuss am 15.10.19 15:18:35

PLUS THERAPEUTICS, Inc. has added a new press release to its website:

Plus Therapeutics Receives $4.6MM Reimbursement Payment

Click here for a complete listing of PLUS THERAPEUTICS, Inc. press releases.

[Malecon]

Plus Therapeutics Receives Fast Track Designation From FDA for Its Novel Glioblastoma Treatment

https://www.globenewswire.com/news-release/2020/09/15/209356…

[SkyrockerZoe]

Die Insider kaufen Hier tut sich was

[Boersaner]

Bullishe Kerzen

Jetzt fehlt nur mehr die Zündung.

[Hubertuss]

Plus Therapeutics teilt Glanz nach zwei Meilensteinen bei der Herstellung seines führenden Radiotherapeutikums

Plus Therapeutics Inc PSTV +0% (Get Free Alerts for PSTV) hat zwei wichtige Meilensteine auf dem Weg zur cGMP-Herstellung von Rhenium-186 NanoLiposom (186RNL) erreicht.

Das Unternehmen hat mit IsoTherapeutics Group LLC einen Master-Services-Vertrag (MSA) zur Entwicklung, Herstellung und Lieferung des Rhenium-186-Isotops für sein zu prüfendes Strahlentherapeutikum 186RNL abgeschlossen.
Die Vereinbarung wird dazu beitragen, dass Rhenium-186 die FDA-Anforderungen für den Einsatz in klinischen Studien im Spätstadium erfüllt.

Im Zusammenhang:
Die gezielte Strahlentherapie von Plus Therapeutics zeigt, dass das Gesamtüberleben in der Hirntumorstudie förderlich ist .
Im Rahmen der MSA wird IsoTherapeutics einen Syntheseprozess und prozessinterne Fertigungskontrollen, die Entwicklung und Validierung von Testmethoden, Stabilitätsstudien entwickeln und Rhenium-186 herstellen.
Darüber hinaus hat Plus Therapeutics den Technologietransfer analytischer Testmethoden mit Piramal Pharma Solutions (PPS) für das Zwischenprodukt des Arzneimittelprodukts 186RNL abgeschlossen.
Wie bereits bekannt gegeben , hat Plus Therapeutics Anfang 2021 ein MSA mit PPS abgeschlossen, um das Zwischenprodukt 186RNL von Plus Therapeutics zu entwickeln, herzustellen und zu liefern.

Price Action:
PSTV-Aktien sind während der Premarket-Sitzung am letzten Check-Dienstag um 48,50% auf 1,62 USD gestiegen.


Quelle: https://www.benzinga.com/general/biotech/22/01/24876878/plus…


Gruß

[edlinger007]

Antwort auf Beitrag Nr.: 69.766.002 von Boersaner am 01.11.21 15:08:46

Plustherapeutics ist back

Plus therapeutics kommt wieder.
Gute News
Gute Chancen für day trader
KAUFEMPFEHLUNG

[bödel]

100% Plus ist auch nicht schlecht und USA hat noch nicht einmal gestartet

[bödel]

https://www.globenewswire.com/news-release/2022/08/17/250043…

[bödel]

[bödel]

USA Vormarkt : 1.200 +0.649 +117.79% 05:45 08/18 EDT

[bödel]

Plus Therapeutics erhält 17,6 Millionen US-Dollar vom Bundesstaat Texas

[bödel]

Vormarkt : 1.280 +0.729 +132.30% 05:45 08/18 EDT